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Success for gene therapy clinical protocols depends on the design of safe and efficient
gene carriers. Nature had already designed efficient DNA or RNA delivery devices, namely
virus particles. However, the risk of insertional mutagenesis has limited their clinical use.
Alternatively, safer approaches involving non-viral carriers have been and continue to be
developed. While they have been reported to be less efficient than viral vectors, adding
genome editing elements to pDNA makes the integration of corrective sequence site specific
moving non-viral gene delivery systems closer to clinical applications. Over the last decade,
peptides have emerged as a new family of potential carriers in gene therapy. Peptides
are easy to synthesize, quite stable and expected to produce minimally immunogenic and
inflammatory responses. We recently reported on a new class of Branched Amphiphilic
Peptides Capsules (BAPCs) that self-assemble into extremely stable nano-spheres. BAPCs
display a uniform size of ∼20 nm if they are incubated at 4◦C and they retain their size at
elevated temperatures. In the presence of DNA, they can act as cationic nucleation centers
around which DNA winds generating peptide-DNA complexes with a size ranging from 50nm
to 100nm. However, if BACPs are not incubated at 4◦C, the pattern of interaction with
DNA differs. Depending of the peptide/DNA ratios, the peptides either coat the plasmid
surface forming nano-fibers (0.5-1 µM in length) or condense the plasmid into nano-sized
structures (100-400nm). Different gene delivery efficiencies are observed for the three types
of assemblies. The structure where the DNA wraps around BAPCs display much higher
transfection efficiencies in HeLa cells in comparison to the other two morphologies and the
commercial lipid reagent Lipofectinr. As a proof of concept, pDNA was delivered in vivo,
as a vaccine DNA encoding E7 oncoprotein of HPV-16. It elicited an immune response
activating CD8+ T cells and provided anti-tumor protection in a murine model.
BRANCHED AMPHIPHILIC PEPTIDES: AN ALTERNATE
NON-VIRAL GENE DELIVERY SYSTEM
by
LUZ ADRIANA AVILA FLORES
B.S., Universidad Auto´noma de Madrid, Spain, 2007
M.S., Universidad del Pais Vasco, Spain, 2008
A DISSERTATION
submitted in partial fulfillment of the
requirements for the degree
DOCTOR OF PHILOSOPHY
Department of Biochemistry and Molecular Biophysics
College of Arts and Sciences
KANSAS STATE UNIVERSITY
Manhattan, Kansas
2014
Approved by:
Major Professor
John M. Tomich
Copyright
LUZ ADRIANA AVILA FLORES
2014
Abstract
Success for gene therapy clinical protocols depends on the design of safe and efficient
gene carriers. Nature had already designed efficient DNA or RNA delivery devices, namely
virus particles. However, the risk of insertional mutagenesis has limited their clinical use.
Alternatively, safer approaches involving non-viral carriers have been and continue to be
developed. While they have been reported to be less efficient than viral vectors, adding
genome editing elements to pDNA makes the integration of corrective sequence site specific
moving non-viral gene delivery systems closer to clinical applications. Over the last decade,
peptides have emerged as a new family of potential carriers in gene therapy. Peptides
are easy to synthesize, quite stable and expected to produce minimally immunogenic and
inflammatory responses. We recently reported on a new class of Branched Amphiphilic
Peptides Capsules (BAPCs) that self-assemble into extremely stable nano-spheres. BAPCs
display a uniform size of ∼20 nm if they are incubated at 4◦C and they retain their size at
elevated temperatures. In the presence of DNA, they can act as cationic nucleation centers
around which DNA winds generating peptide-DNA complexes with a size ranging from 50nm
to 100nm. However, if BACPs are not incubated at 4◦C, the pattern of interaction with
DNA differs. Depending of the peptide/DNA ratios, the peptides either coat the plasmid
surface forming nano-fibers (0.5-1 µM in length) or condense the plasmid into nano-sized
structures (100-400nm). Different gene delivery efficiencies are observed for the three types
of assemblies. The structure where the DNA wraps around BAPCs display much higher
transfection efficiencies in HeLa cells in comparison to the other two morphologies and the
commercial lipid reagent Lipofectinr. As a proof of concept, pDNA was delivered in vivo,
as a vaccine DNA encoding E7 oncoprotein of HPV-16. It elicited an immune response
activating CD8+ T cells and provided anti-tumor protection in a murine model.
Table of Contents
Table of Contents vi
List of Figures x
List of Tables xii
Acknowledgements xii
Dedication xiv
Preface xv
1 Synthetic in vitro Delivery Systems For Plasmid DNA in Eukaryotes 1
1.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Synthetic nonviral DNA carriers . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Cationic Lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3.1 Liposomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.4 Polymeric DNA carriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.4.1 DNA complexation, cellular uptake and DNA release . . . . . . . . . 17
1.4.2 Cytotoxicity of polyplexes . . . . . . . . . . . . . . . . . . . . . . . . 20
1.5 Polysaccharide-Based DNA Carriers . . . . . . . . . . . . . . . . . . . . . . . 21
1.5.1 Cyclodextrins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.5.2 Chitosan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.6 Peptide DNA carriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
vi
1.6.1 DNA-Complexation, cellular uptake and DNA release . . . . . . . . . 25
1.6.2 Peptide Cytotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.7 Inorganic Nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.7.1 Gold Nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.7.2 Carbon Nanotubes . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.8 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2 Branched amphiphilic cationic oligo-peptides form peptiplexes with DNA:
A study of their biophysical properties and transfection efficiency 32
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.2.1 Peptide synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.2.2 Preparation of bis(h9:h5)-K-K4 peptiplexes . . . . . . . . . . . . . . . 37
2.2.3 Confocal Laser Scanning microscopy . . . . . . . . . . . . . . . . . . 38
2.2.4 STEM sample preparation . . . . . . . . . . . . . . . . . . . . . . . . 38
2.2.5 Atomic force microscopy (AFM) . . . . . . . . . . . . . . . . . . . . . 38
2.2.6 Determination of zeta potential . . . . . . . . . . . . . . . . . . . . . 39
2.2.7 Gel Electrophoresis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2.2.8 Plasmid digestion with DNase-1 . . . . . . . . . . . . . . . . . . . . . 40
2.2.9 Cell Culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.2.10 Temperature Dependence on Cellular uptake and Lysosomal co-localization
of bis(h9:h5)-K-K4 peptiplexes . . . . . . . . . . . . . . . . . . . . . . 40
2.2.11 pEGFP-N3 plasmid transfection . . . . . . . . . . . . . . . . . . . . . 41
2.2.12 Cell viability assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.3 Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.3.1 Gene delivery and viability assays of bis(h9:h5)-K-K4 peptiplexes . . . 43
vii
2.3.2 Biophysical characterization of bis(h9:h5)-K-K4 peptiplexes . . . . . . 47
2.3.3 Uptake and cellular co-localization of bis(h9:h5)-K-K4 peptiplexes . . 52
2.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3 Branched Amphiphilic Peptide Capsules (BAPCs) for delivery of plasmid
DNA vaccines. 56
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.2.1 Peptide synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.2.2 BAPCs preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.2.3 Preparation of BAPCs-DNA complexes . . . . . . . . . . . . . . . . . 60
3.2.4 STEM sample preparation . . . . . . . . . . . . . . . . . . . . . . . . 60
3.2.5 Atomic force microscopy (AFM) . . . . . . . . . . . . . . . . . . . . . 61
3.2.6 Determination of zeta potential . . . . . . . . . . . . . . . . . . . . . 61
3.2.7 Plasmid digestion with DNase-1 . . . . . . . . . . . . . . . . . . . . 62
3.2.8 DNA/Capsule interaction study with two BAPC temperature variants 62
3.2.9 Cell Culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.2.10 Confocal Laser Scanning microscopy . . . . . . . . . . . . . . . . . . 62
3.2.11 pEGFP-N3 plasmid transfection . . . . . . . . . . . . . . . . . . . . . 63
3.2.12 Transfection with pEGFP-N3 plasmid previously treated with DNase I 63
3.2.13 Cell viability assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.2.14 DNA vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.2.15 Tumor cell challenge . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.2.16 Intracellular cytokine staining . . . . . . . . . . . . . . . . . . . . . . 65
3.3 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.3.1 In vitro Transfection Efficiency of the BAPCs-DNA complexes . . . . 65
viii
3.3.2 In vitro toxicity of BAPCs-DNA complexes . . . . . . . . . . . . . . . 67
3.3.3 Biophysical characterization of DNA/BAPC complexes . . . . . . . . 67
3.3.4 DNA/Capsule interaction study with two BAPC temperature variants 72
3.3.5 Delivery of HPV-Specific therapeutic antitumor DNA vaccines . . . . 73
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4 Conclusions 77
4.1 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Bibliography 82
A Supplementary Data for Chapter 2 109
B Supplementary Data for Chapter 3 111
ix
List of Figures
1.1 Current synthetic DNA delivery vectors . . . . . . . . . . . . . . . . . . . . . 4
1.2 Different structural components of cationic lipids: hydrophilic headgroup,
linker bond, and hydrophobic domain . . . . . . . . . . . . . . . . . . . . . . 7
1.3 Structures of the most common synthetic polymers used for gene delivery . . 13
1.4 The structure of the single cyclized polymer knot . . . . . . . . . . . . . . . 17
1.5 Synthesis of MWCNT-CSFA NP hybrids . . . . . . . . . . . . . . . . . . . . 29
1.6 Biocompatible multi-walled carbon nanotube-chitosanfolic acid nanoparticle
hybrids as GFP gene delivery materials . . . . . . . . . . . . . . . . . . . . . 30
2.1 Structure of the branched amphiphilic peptides . . . . . . . . . . . . . . . . 35
2.2 Peptiplex preparation method . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.3 Comparison of transfection efficiency of the peptiplexes in HeLa cells . . . . 45
2.4 Cell viability of HeLa cells after treatment with peptiplexes . . . . . . . . . . 47
2.5 TEM images of the peptiplexes at different peptide to DNA ratios . . . . . . 48
2.6 Branched peptide sequences interacting with DNA . . . . . . . . . . . . . . . 49
2.7 AFM images of the peptiplexes . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.8 Zeta potential and Agarose gel electrophoresis of peptiplexes . . . . . . . . . 51
2.9 Cellular uptake of the peptiplexes at different temperatures . . . . . . . . . . 53
2.10 Lysosomal co-localization of the peptiplexes incubated at 37 ◦C with 50 µM
30% Rhodamine B label . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
2.11 Transient EGFP expression of the peptiplexes . . . . . . . . . . . . . . . . . 55
x
3.1 S/TEM image of BAPCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.2 Peptiplex preparation method . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.3 Transfection efficiency of BAPCs-DNA complexes in HeLa cells . . . . . . . 66
3.4 Cell viability as determined by trypan blue analysis . . . . . . . . . . . . . . 68
3.5 TEM images of the BACP:DNA assemblies at N:P = 20.8 . . . . . . . . . . 69
3.6 AFM images of the DNA/BAPCs at N:P = 20.8 . . . . . . . . . . . . . . . . 70
3.7 Gel shifts and Zeta potentials of DNA/BAPCs . . . . . . . . . . . . . . . . 71
3.8 DNA/capsule interaction study . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.9 Administration of a single vaccine dose containing DNA/BACP’s complexes
at different N:P charge ratios . . . . . . . . . . . . . . . . . . . . . . . . . . 74
3.10 Percentage of CD8+ IFN-γ+ cells of total CD8+ T cells in mice immunized
with different DNA/BAPC complexes at different N:P charge ratios. . . . . . 75
4.1 TEM images of different DNA/peptide assemblies . . . . . . . . . . . . . . . 79
A.1 Comparison of transfection efficiency of the peptide control sequences . . . . 109
A.2 Agarose gel electrophoresis of peptide complexes with different peptide se-
quences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
A.3 Comparison of transfection efficiency of the peptide control sequences . . . . 110
B.1 Cell viability after treatment with DNA/BAPC complexes at different N:P
charge ratios as determined by PI analysis . . . . . . . . . . . . . . . . . . . 111
xi
List of Tables
1.1 Luciferase expression in various mammalian cell lines transfected with cationic
lipids commonly used for gene transfer (RLU/per 96-well) . . . . . . . . . . 6
1.2 Luciferase expression in various mammalian cell lines transfected with cationic
lipids commonly used for gene transfer (RLU/per mg/protein) . . . . . . . . 9
1.3 Luciferase expression in various mammalian cell lines transfected with cationic
polymers commonly used for gene transfer (RLU/per 96-well) . . . . . . . . 15
1.4 Transfection efficiency (%) using the reporter plasmid pEGFP (Enhanced
Green Fluorescence Protein) in various mammalian cell lines transfected with
cationic polymers commonly used for gene transfer . . . . . . . . . . . . . . 16
xii
Acknowledgments
The results presented in this dissertation are not exclusively the result of my effort, but
also of various collaborations and partnerships.
I would like to thank my advisor Dr. John Tomich, for whom I have a deep admiration
and respect, both as a person and as a scientist. He trained me to be an independent
researcher and taught me that taking risks in my research is sometimes the way to accomplish
great and original results. I appreciate the freedom he gave me to pursue various projects
without objection.
I thank my committee members: Dr. Stella Lee who is my primary resource for get-
ting answers and scientific advice in regard to cell biology and cell culturing; Dr. Michael
Zolkiewski for providing advice many times during my graduate school career and for many
insightful discussions and suggestions that in addition to saving me time, provided rigor to
my work; Dr. Phillip Klebba for their helpful career advice and suggestions in general; Dr.
Jianhan Chen for his useful ideas regarding molecular modeling; and Dr. Meena Kumari,
the chairperson of the examining committee.
I would like to thank the people who contributed to generate the microscopy images,
Dr. Robert Szoszkiewicz and Nicoleta Ploscariu for the AFM analysis, Dr. Yoonseong Park
and Dr. Ladislav Simo for the great confocal pictures and Dr. Prem thapa, from KU who
helped me with the TEM studies.
I am very grateful to our collaborators at the Sa˜o Paulo University, Dr. Lu´ıs C.S. Ferreira
and Luana Aps for the in vivo vaccination assays carried out in their laboratory and also
for allowing me to realize that I understand Portuguese!
I thank my lab members, Dr. Pinakin Sukthankar, Ben Katz, Jammie Laymann, Susan
Whitaker and other past members, Dr. Yasuaki Hiromasa, Dr. Sushanth Gudlur , Rachael
xiii
Ott and the new arrivals, Patricia Games who created a friendly atmosphere that made me
feel at home.
I also thank my friends Nicole Green, Jordan Woehl and Chester McDowell for the
occasionally Bloody Marys that made life easier when results didn’t come out as expected.
I also thank friends from other labs, Sara Duhachek Muggy, Prashant Wani, Rohit Kamat,
Lorne Jordan, Yan Shipelskiy and Stacy Littlechild for entertaining discussions about life
and experiments.
I especially thank my family, my Dad who unfortunately is not here to share this moment
with me but who seeded in me the scientific curiosity since I was a child and my Mom who
sacrificed her life for my education. I thank my brothers, Adolfo Avila, Ce´sar Avila and my
oldest brother Germa´n Avila who I will always miss. I thank particularly my sister, Silvia
Avila, a busy entrepreneur and Mom who always find time to help me if I am in trouble,
who is my best friend and who always encourage me to pursue my professional and personal
dreams.
I thank my in-laws, nephews and nieces for the affection provided along these years.
I thank particularly my brother in law, Jose Luis Castrillo who has been very supportive
during my career and to my little and wonderful niece, Leire Castrillo who brought happiness
and funny moments to my life.
There is a very important person in my life to who I owe special thanks, my fiance´e
Guillaume Laurent, an excellent physicist and great person who has been my partner and
best friend for several years and with who I share a philosophy about how to life live. Thanks
for the unconditional support, patience and love during these four years of graduate school.
I appreciated your cheer and practical advice during the bad and frustrating moments. Also,
thanks for teaching me computer programs that made my life easier and for your help in
editing this manuscript.
xiv
Dedication
To my parents (Pedro Avila and Ma. Luisa Flores) to my sister (Silvia Avila) and
my fiance´e (Guillaume Laurent), for their patience and the moral and financial support to
pursue this dream.
xv
Preface
“And Jesus said to him, If you can! All things are possible to him who believes” Mark
9:23
xvi
Chapter 1
Synthetic in vitro Delivery Systems
For Plasmid DNA in Eukaryotes
This chapter has been reproduced in its current format with permission from L. Adriana
Avila, Stella Y.Lee and John M. Tomich, Journal of Nanopharmaceutics and Drug Delivery,
2:1-19, 2014. c©American Scientific Publishers .
1.1 Introduction
Not until the early 1960s was foreign DNA introduced as-permanent, stable, functional, and
hereditable elements into mammalian cells1. With this achievement new approaches for
treating human diseases became imaginable. Theoretically, the insertion of DNA to correct
genes that are either absent or miscoded could ameliorate many genetic disorders. Since
then, an increasing number of methods have been and are currently being developed for
delivering DNA into cells.
Besides plasmid DNA (pDNA), various types of RNA molecules have been introduced
into cells. In contrast to pDNA, which is used to introduce a new or corrected copy of the
defective gene, RNA is used to inhibit translation of mRNAs,2 in a transient fashion3,4.
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Plasmid DNA can also be used as genetic vaccines leading to activation of specific immune
responses either preventing or treating infectious or degenerative diseases5,6,7.
The delivery of foreign genetic material involves overcoming several extracellular and
cellular barriers. For in vitro delivery, nucleic acids must cross the cell membrane, then
avoid lysosomal degradation and then traverse the nuclear membrane, and achieve thera-
peutic levels of expression without disrupting other genes8. For in vivo delivery additional
challenges must be overcome. The added genetic material has to be protected from circu-
lating nucleases present in the organism, phagocyte degradation, aggregation with serum
proteins and finally target specific tissues4. Furthermore, when used to target central ner-
vous tissues, the genetic material must efficiently cross the blood-brain barrier to reach the
targeted cells9.
In vivo, cells can take up naked DNA however the mechanism is not fully understood.
Injections of naked DNA into skeletal muscle may result in the expression of the proteins
coded by the added DNA however at low and extremely variable levels10. For this reason the
development and use of molecular carriers that both coat and shield the nucleic acids from
hydrolysis by nucleases and target the negatively charged DNA to specific tissues is vital.
Nature had already designed efficient DNA or RNA delivery devices, namely virus particles.
Viruses effectively package, protect and deliver genetic material. Researchers seized on this
approach and began working with certain viruses for use as human gene delivery systems.
Adenovirus and retrovirus were the first carriers used to delivery therapeutic genes. At
present, they remain the vectors of choice, showing the highest efficiency11. One of the
advantages of viral gene delivery system is that a gene can be integrated into the host’s
genome. However, the death of a patient receiving an adenoviral vector triggered safety
objections and questioned the further use of viral vectors12. Also, other issues including the
potential risk of insertional mutagenesis, previously established immunity to the virus vector,
and the size limitation on the DNA that can be packaged have limited clinical applications13.
Despite these risks, researchers continue working to improve the efficacy and safety of these
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vectors. In recent years, research has focused on the use of lentivectors, which, like their
retrovirus counterparts, are devoid of viral proteins, not replication competent, and able
to transduce non-dividing cells14. Currently, these lentivectors are being used in about
3.3% (n = 67) of clinical trials (http://www.wiley.co.uk/genmed/clinical/ [July 2013])15.
Alternatively, non-viral biological methods are being investigated for DNA delivery as safer
systems16. While somewhat less efficient than their viral counterparts, significant progress
has led to improved transfection efficiencies and made them feasible alternatives. With the
newly developed genome editing, such as CRISPR/Cas9 and zinc-finger nuclease (ZFN)
systems, integration of the corrected gene into the genome can be site specific17,18. When
incorporating genome editing elements to pDNA, non-viral gene delivery can provide a
significant refinement for gene therapy.
Non-viral synthetic systems employ biocompatible molecules that facilitate the uptake of
nucleic acids into cells. Synthetic carrier methods first require the complexation of cationic
amphiphilic molecules with anionic nucleic acids followed by cellular uptake through a fa-
cilitated membrane translocation. The application of these newer methods ranges from
preclinical studies to human trials. Lipid base vectors now account for the 5.5% (n=112)
of gene therapy clinical trials (http://www.wiley.co.uk/genmed/clinical/ [July 2013]). The
biggest challenge for non-viral gene therapy will be translation from bench to clinical appli-
cations19. This review focuses on the most recent (2010-present) non-viral pDNA delivery
systems in vitro and compares their transfection efficiencies and potential.
1.2 Synthetic nonviral DNA carriers
Synthetic non-viral DNA carriers are cationic molecules that bind to DNA, predominantly
through electrostatics. Cationic lipids, polysaccharides, peptides, synthetic polymers, and
metals are examples of molecules that are currently used as chemical DNA carriers (Figure
1.1). The electrostatic interactions between the chemical vectors and pDNA generate com-
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plexes with different topologies; either spherical vesicles, rod-like or ordered multi-laminar
structures20.
Figure 1.1: Current synthetic DNA delivery vectors.
These complexes even with incorporated DNA retain their net positive charges, facili-
tating interactions with negatively cell membrane surfaces21,22 Natural Glycosaminoglycan
chains such the sulfated forms of heparin, dermatan and chondroitin, are responsible for
the eukaryotic cell membrane’s negative potential23. Once bound, endocytosis serves as the
principle route of uptake of the polycation/DNA complexes24,25,21. Endocytosis in itself is
a broad term that encompasses specific pathways. They can be broadly classified in four
types: phagocytosis, clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis
(CvME) and macropinocytosis26. According to several reports there is no evidence linking
the mode of entry to transfection efficiency27,24. It is generally assumed that low to mod-
erate gene expression is due mostly to the trapping and degradation of the pDNA within
intracellular vesicles and limited translocation to the nucleus28,16.
Due to their cationic nature, non-viral nanocarriers can be toxic29 The integrity of
organelle membranes can be compromised and undesirable interactions with other negatively
charge compounds such nucleic acids and proteins could affect the protein expression and
other natural cellular process30. Factors that have a direct impact in cytotoxicity are:
charge density, molecular weight, presence of free carrier and degree of biodegradability31.
Currently, research on how to improve the transfection efficiency without compromising cell
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viability remains the largest obstacle for non-viral DNA/RNA delivery in vitro.
1.3 Cationic Lipids
Cationic lipids are the most commonly used synthetic gene delivery molecules due to their
high transfection efficiency. The most common systems for gene delivery using lipids are:
liposomes, solid lipid nano particles and micelles32. Cationic lipids used for DNA delivery
generally contain four functional domains: a hydrophilic head-group, a linker, a backbone
domain, and a hydrophobic domain33 (Figure 1.2). The most commonly hydrophilic head
groups are primary-, secondary-, tertiary-amines, or quaternary ammonium salts. However,
guanidino, imidazole, pyridinium, can be present34,35. The hydrophobic tails are usually
made of two types of hydrophobic moieties, aliphatic chains or steroids. The most com-
mon linkages between the hydrophilic head and hydrophobic moieties are ethers, esters,
carbamates, or amides36. The structure of cationic lipids is a major factor for their trans-
fection activity and toxicity36. Masotti et al.37 have compared different parameters of some
commercially available cationic lipids influencing toxicity and transfection efficiency on Rat
Glioma Cell Line (C6) (Table 1.1).
A pioneering design by Felgner et al.38 was the glycerol backbone-based cationic trans-
fection lipid-DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N, N, N-trimethylammonium chloride).
Since then a number of compounds have been developed and display considerable diversity in
structure, number of aliphatic chains, asymmetry, chain length and degrees of unsaturation.
Often they are combined with neutral helper lipids such dioleoyl phosphatidylethanolamine
(DOPE) and 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) to yield higher transfection
efficiencies in many cell types.
Mevel et al.40 reported on the synthesis of a novel cationic lipid: N’, N’-dioctadecyl-
N-4, 8-diaza-10-aminodecanoylglycine amide (DODAG). This cationic lipid contains two
chains in the hydrophobic domain and a guanidinium functional group. Using DODAG in
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Transfection efficiency
(RLU/per 96-well)
Lipid/DNA
charge ratios
Incubation
time
Serum Ref.
R
at
G
li
om
a
(C
6)
DOTAP/DOPE 5×105 1:1 4h + [37]
DC-Chol/DOPE 4×105 5:1 4h - [37]
DDAB/DOPE 1×105 2.5:1 4h + [37]
FUGENE++ 4×106 - 4h + [37]
DMRIE/Chol 8×104 2.5:1 4h - [37]
LIPOFECTIN 4×105 5:1 4h - [37]
LIPOFECTAMIN
2000
1.1×105 4:1 4h - [37]
CELLEFECTIN 6×104 2.5:1 4h - [37]
C
H
O
DOTAP/DOPE 1.1×105 5:1 4h - [39]
OLON/DOPE 2×106 5:1 4h - [39]
LHON/DOPE 2.5×106 3:1* 4h - [39]
CTAB/DOPE 5×104 2:7* 4h - [39]
DOGSH/DOPE 4×105 3:1 4h - [39]
Table 1.1: Luciferase expression in various mammalian cell lines transfected with cationic
lipids commonly used for gene transfer. Transfection efficiency is expressed in Relative
Light Units (RLU). The comparison was done at the optimal charge/ratio (that one that
shows be more efficient) of each liposome formulation after 24h of transfection. *Rep-
resents the w/w ratio. ++Fugene has a protected formulation. Abbreviations: DC-Chol:
cholesteryl-3b-N-(dimethyl-aminoethyl)carbamate hydrochloride DDAB: dimethyldioctadecy-
lammonium bromide. DMRIE: 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium
bromide. CELLEFECTIN: 1:1.5 molar mixture of the cationic lipid N, N, N, N -tetra-
methyltetrapalmityl-spermine (TM-TPS) and DOPE. DOGSH: 19,29-dioleyl-sn-glycero-39-
succinyl-1, 6-hexanediol CHO: Chinese Hamster Ovary.
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Figure 1.2: Different structural components of cationic lipids: hydrophilic headgroup, linker
bond, and hydrophobic domain. Reprinted with permission from ref. 33, D. Zhi, S. Zhang,
S. Cui, Y. Zhao, Y. Wang, D. Zhao, The Headgroup Evolution of Cationic Lipids for Gene
Delivery, Bioconjugate Chem, 24, 487519 (2013). Copyrightr 2013, American Chemical
Society.
combination with the helper lipid DOPE three cell lines were transfected obtaining high
levels of luciferase expression compared to Lipofectamine 2000 (Table 1.2). They reported
as well moderate cytotoxicity; only around 5% of LDH release was found using immortal-
ized adherent cell lines. For the same type of cell line, around 20% lactate dehydrogenase
(LDH) release (equivalent to cell death) has been reported for Lipofectamine 2000. Safinya
and co-workers41 have designed a cationic lipid (CMVL5) that contains a disulfide bond
spacer between the headgroup and the hydrophobic tails. The objective of this modifica-
tion was to facilitate the degradation in the reductive environment of the cytoplasm and
with this decrease the cytotoxicity. Although, the transfection efficiency was similar than
Lipofectamine 2000, cell viability was 10% more than what was reported for the commercial
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reagent. Zhi et al.33 have reported similar results in terms of transfection and cytotoxicity
but using carbamate linkages between the ammonium heads and the hydrocarbon chains.
Medvedeva et al.,42 synthesized a biodegradable cholesterol-based (CcHPB), obtaining 22%
GFP expression on HEK 293 (Human Embryonic Kidney 293) cells. While significant trans-
fection efficiencies have also been reported for single-tailed cationic lipids, for to most part
single-tailed and three-tailed cationic lipids appear to be more toxic and less efficient than
their double-tailed counterparts38. Examples of single-tailed cationic lipids include: cetyl
trimethylammonium bromide (CTAB), oleoyl ornithinate (OLON), and 6-lauroxyhexyl or-
nithinate (LHON)39 (Table 1.1).
Comparison of transfection efficiencies of lipophophoramidates43 and Biotinylated44 cationic
lipids formulations are show in Table 1.2.
1.3.1 Liposomes
Liposomes are lipid vesicles that are usually formed through the self-assembly of cationic
di-acyl phospholipids which are amphiphilic in nature. The first lipid vesicle reported was
formed by the dispersion of phospholipids in water by Bangham and coworkers45. Since then,
a number of structurally diverse lipid vesicles have been developed. Unlike polypeptides,
polysaccharides and polynucleotides, lipids are not polymers, by definition, however they
are rarely found as monomers46. They prefer to assemble into macromolecular assemblies,
such micelles and vesicles to escape exposure of the hydrophobic segments to water. Lipid
vesicles will have different sizes depending on the method of preparation. Vesicle sizes fall
into the nanometer to micrometer range47. Liposomes have found uses in many biological
and pharmaceutical applications including diagnostic agents and drug delivery vehicles.
A major limitation for liposomes, in vivo, is the short circulating half-life48. Systemic
elimination of cationic lipids takes place upon formation of larger aggregates via their in-
teractions with the negatively charged serum molecules or cellular components (primarily
erythrocytes and platelets). Surface shielding through the use of hydrophilic and charge
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Transfection efficiency
(RLU/per mg/protein)
Lipid/DNA
charge ratios
Incubation
time
Serum Ref.
H
eL
a
LIPOFECTIN 3.3×105 5:1 4h - [40]
LIPOFECTAMINE 4.8×107 2.5:1* 4h + [40]
DODAG/DOPE 1.3×108 4:1* 4h + [40]
CDAN/DOPE 5×107 8:1* 4h + [40]
CAPG/DOPE 2×107 2:1* 4h + [40]
KLN47 1×107 2:1 4h - [43]
BSV10 1×106 2:1 4h - [43]
BSV36 1×107 2:1 4h - [43]
DDCTMA 3.2×105 2:1 N/A N/A [43]
S
W
B
-9
5
DOTAP/Chol 8×106 1:1 1h + [35]
2Oc 1×107 1:1 1h - [35]
H
E
K
-2
93
Lipofectamine 1×1011 N/A 4h + [44]
5c 1×109 8:1 4h + [44]
Table 1.2: Luciferase expression in various mammalian cell lines transfected with cationic
lipids commonly used for gene transfer. Transfection efficiency is expressed in Relative Light
Units (RLU). The comparison was done at the optimal charge/ratio (that one that shows
be more efficient) of each liposome formulation after 24h of transfection. *Represents the
w/w ratio. Abbreviations: CDAN: N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine.
CAPG: N1-cholesteryloxycarbonyl-3-aza-pent-1-amino-5-guanidiniumchloride. DDCTMA:
N-[1-(2,3-didodecylcarbamoyloxy)propyl]-N,N,N-trimethylammonium iodide. 2Oc: 1-(2,3-
dioleoyloxy-propyl)-2,4,6-trimethylpyridinium. KLN47: trimethylarsonium Lipophospho-
ramidate polar head. BSV36: trimethylammonium polar head. BSV10: guani-
dinum polar head. DDCTMA: N-[1-(2,3-didodecyl carbamoyloxy)propyl]-N-ethyl-N,N-
dimethylammonium iodide. SWB-95: Brain Glioma. HEK-293: Human Embryonic Kidney
293.
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neutral polymers such as polyethylene glycol (PEG) to reduce excessive chargecharge inter-
action appears very effective in prolonging the circulation half-life of lipoplexes49. However,
some reduction in the overall transfection efficiency has been reported49.
DNA complexation, cellular uptake and DNA release
Cationic liposomes when mixed with pDNA, in aqueous solutions, are capable of self-
assembly into different liquid crystalline structures. These structures are called “lipoplexes”
and the morphology of the phase depends on the packing parameter of the lipid molecules.
Two phases appear to be more efficient for mammalian cell transfection: lamellar (Lα) phase
with alternating lipid bilayer and DNA monolayers and inverted hexagonal (HII) phase con-
sisting of DNA coated with a lipid monolayer in a hexagonal lattice. It has been argued
that the HII phase complexes have a much higher transfection rates than do the Lα phase
ones50. One explanation could be that this phase promotes the lipoplex fusion with cellular
membranes facilitating the cellular uptake and the endosomal release51.
A number of recent publications indicate that the usual endocytic routes of uptake for
lipoplexes are: clathrin- and caveolae-mediated endocytosis and/or macropinocytosis21,25,24.
It appears that lipoplexes are not limited to a single uptake pathway; rather they can utilize
several of these pathways. It was observed that the inhibition of one pathway produced
an increase in uptake though the other one (compensatory effect). Also, modifications in
particle size, shape and exposed ligands on the lipoplexes can alter the route of uptake52.
Nevertheless, the method of entry of these structures does not appear to contribute to
transfection efficiency, no direct relationship has been observed53,54. For instance, for two
lipoplex formulations, i.e., DOTAP/DOPC and DCChol/DOPE the same endocytic route
(macropinocytosis) was observed in CHO cells, however the sub-cellular co-localization and
the transfection efficiency was remarkable different. One explanation is that DCChol/DOPE
lipoplexes or their cargos were capable of escaping the endosomes while the DOTAP for-
mulation appeared to accumulate within these sub-cellular compartments55. These results
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suggest that transfection efficiency correlates more directly with the ability of a lipoplex to
escape the lysosome than its method of cellular uptake56.
It has been proposed that for lipid-base systems escape from the endosomal/phagosomal
vesicles is facilitated by membrane fusion and formation of transient pores in the organelles
with the concomitant release of nucleic acids into the cytosol52. The presence of the helper
lipid DOPE in some formulations promotes the transition from lamellar (Lα) phase to hexag-
onal (HII) phase thus helping the insertion of lipoplexes into endosomal membranes
48. This
mechanism has been explained by the phenomenon called “ion paring”. In this scenario the
cationic and anionic phospholipid head groups neutralized each other thereby favoring the
transition to the hexagonal (HII) phase. Upon neutralization, dissociation of the DNA from
the complex occurs57. The results suggest that strong lipid-DNA binding will interfere with
the dissociation process and decrease transfection efficiencies. The incorporation of some
modifications to the cationic lipids such pH sensitive linkers between the head group and the
acyl portion of the molecules can promote enhanced DNA release58. Others have proposed
that shorter hydrocarbon chains in the lipoplexes will increase the fluidity of the bilayer and
favor higher rates of inter-membrane delivery and lipid membrane mixing, resulting in the
increased disruption of the endosomal membrane and DNA escape48.
Cytotoxicity of Lipoplexes
An important issue to address when considering in vivo studies is the toxicity of a specific
nano carrier. Various cellular and tissue responses could lead to altered signaling or phys-
iology, cell death and induced immune responses59. One cause of lipid cytotoxicity is the
interaction of the tertiary or quaternary nitrogen functional groups that bind to and inhibit
enzymes such as PKC60. In addition, cationic liposomes are known to affect the function
of membrane proteins involved in signal cascades implicated in immune responses29. It was
shown that some liposomes will induce immune response in the absence of antigens such
as DOTAP liposomes which can induce expression of monocyte chemo-attractant protein-1
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(MCP-1), macrophage inflammatory protein-1 alpha (MIP-1a) and macrophage inflamma-
tory protein-1 beta (MIP-1b) together with transcription of a dendritic cell maturation
marker, CD11c61. Nevertheless, a novel strategy has been proposed to take advantage
of this specific immune-stimulating (adjuvant) feature to enhance the development of an
anticancer vaccine using the peptide antigen derived from E7 oncoprotein of human papillo-
mavirus (HPV) type 16 mixed with the cationic lipid DOTAP62. While several reports have
described this phenomenon these effects have not been studied in great detail. Also, cationic
lipids have been reported to activate several kinases implicated in immune responses and
regular cell signaling63,64. In addition, cationic lipids fusing with cell membranes could lead
to the insertion of foreign lipids into the membrane65. Having foreign lipids in a membrane
could alter the physio-chemical properties of the bilayer thereby affecting membrane protein
structure, cell signaling and interactions between lipids and protein membranes. It has been
reported that this process can cause non specific inflammatory responses66.
1.4 Polymeric DNA carriers
Polymers used in gene delivery, like their lipid counterparts, are generally cationic in char-
acter. They are made up of a wide variety of polymerized monomers67. The most fre-
quently used to deliver DNA include: Polyethylenimine (PEI)68, poly(α-[4-aminobutyl]-
l-glycolic acid (PAGA)69, Poly(β-Amino Ester) (PBAE)70, poly(amidoamine) (PAMAM),
poly-propylenimine (PPI), Poly(2-(dimethylamino)ethyl methacrylate (DMAEMA)71 and
polyethylene glycol (PEG) (Figure 1.3). They are easy to synthesize, and some of them
including PBAE and PAGA, contain biodegradable linkages designed to reduce cell toxic-
ity. PEI, is one of the most widely studied non-viral vectors due to its high transfection
efficiency. Its highly cationic surface strongly associates with and helps condense DNA
efficiently, however it is one of the most toxic agents being investigated72. Dendrimers,
such PAMAM and PPI are synthetic, hyper-branched spherical molecules that are capa-
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ble of entrapping small molecules within their structures73. Their large size and multiva-
lent surfaces provide an excellent platform for the attachment/associate of different drugs
and therapeutic genes. DMAEMA is a cationic polymer offering the advantage of being a
water-soluble cationic polymer74. PEG is commonly conjugated to some of the polymers
mentioned above to prevent aggregated complexes and to increase stability and circulation
half-life, in vivo 75. Natural occurring polymers in complexion with other molecules, such
as collagen with DMPC76 and gelatin with PEI77 have been tested also as pDNA delivery
vehicles where they have shown promising results and having the advantage of good cyto-
compatibility. These properties have made these molecules popular choices in areas outside
of gene delivery namely, tissue engineering scaffolding applications78.
Figure 1.3: Structures of the most common synthetic polymers used for gene delivery.
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Recently, Newland et al.,79 reported on a new polymeric gene vector formed predomi-
nantly through internal cyclization reactions within the polymer instead the usual hyper-
branching between polymer chains. Ethylene glycol dimethacrylate (EGDMA) was the cy-
clizing unit while 2-(Dimethylaminoethyl) methacrylate (DMAEMA) was the cationic unit.
Despite the multi-step and synthesis of the polymer involving a dialysis process for several
days, significant transfection efficiencies and moderate toxicity was observed when compared
to commercial agents such as SuperFectr (partially degraded PAMAM) and PEI (Figure
1.4, Table 1.3 and 1.4). Zhou et al.,80 synthesized a family of biodegradable poly(amine-
co-esters) formed through enzymatic copolymerization of di-esters with amino-substituted
diols. They reported very high transfection efficiencies and low toxicity in comparison to
polyethylenimine and Lipofectamine 2000. However, the formation of the poliplexes has to
be done under slightly acidic conditions and in the presence of DMSO. These conditions
could be a drawback for some sensitive cell lines. Keeney et al.,81 reported on a poly(β-
amino ester) biodegradable system for the efficient delivery of Mini Circle MC-DNA that
gave significant GFP expression (Table 1.4). MC-DNA is a small supercoiled DNA molecule
where the bacteria cassette commonly used in plasmids has been removed. They created
a small library of 18 poly(β-amino ester) polymers differing in the backbone structure and
the end-group chemistry. Subsequently, these polymers were tested in embryonic kidney
293 cells and mouse embryonic fibroblasts obtaining excellent transfection rates in some of
them. In this study they demonstrated that higher transfection efficiency can be achieved
for HEK cells using the MC-DNA instead the conventional plasmid.
Different materials have been combined with polymers to form hybrid gene delivery
nanoparticles in order to improve the stability, targeting and the circulating half-life in
blood82,83,84,85. Majoros et al.,86 reported folate-mediate targeting where the poly(amidoamine)
(PAMAM) dendrimer was conjugated to folic acid. These folate residues bind to folate re-
ceptors that are overexpressed in some cancer cells87. Comparisons of some commercial
available polymeric-base transfection reagents88 are shown in Table 1.4.
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Transfection efficiency
(RLU/per 96-well)
Lipid/DNA
charge ratios
Incubation
time
Serum Ref.
H
eL
a
Arrest In 5.4×105 5:1 4h + [88]
Express Fect 2.9×105 1:1 4h + [88]
JetPEI 6.5×105 2:1 4h + [88]
SuperFect 2.2×106 5:1 4h + [88]
Dextran-
Spermine
4×105 5:1 4h - [88]
Collagen 1×105 4:1 4h - [88]
C
H
O
PEI 800 Da 4×106 18 4h - [89]
PEI 25kDa 3×1010 9 4h - [89]
PEI-DSP 8×109 9 4h - [89]
PEI-DTBP 3×108 9 4h - [89]
Table 1.3: Luciferase expression in various mammalian cell lines transfected with the indi-
cated cationic polymers commonly used for gene transfer. Transfection efficiency is expressed
in Relative Light Units (RLU). The comparison was done at the optimal charge/ratio (that
one that shows be more efficient) of each polyplex formulation after 48 h of transfection. Ab-
breviations: DSP: cross-linking reagent, di-thio-bis(succinimidylpropionate). DTBP: cross-
linking reagent dimethyl 3,3’-dithiobispropionimidate 2HCl.
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% Cells transfected Polymer/DNA
charge ratios
Incubation
time
Serum Ref.
1
0
18
Chitosan/γ-PGA 54 10:1:14* 4h - [90]
Lipofectamin
2000
33 N/A 4h - [90]
P
M
S
C
s Fugene 15 N/A 4h - [91]
PEI-β-CD 12 N/A 4h - [91]
TAT-PEI-β-CD 16 N/A 4h - [91]
H
E
K
-2
9
3
PEI 25KDa 10 15 4h + [92]
PEI 1.8KDa 4 90 4h + [92]
PAMAM G5 22 90 4h + [92]
PAMAM G1 18 10 4h + [92]
PAMAM G2 8 50 4h + [92]
EA-G1 18 50 4h + [92]
EA-G2 43 50 4h + [92]
PEI-25KDa 12 15 4h + [92]
Lipo-2k 23 6 4h + [92]
H
eL
a
PEI 30 5:1 2h - [93]
CTS 18 7 2h - [93]
NMCTS-graft-
PAMAM
36 5:1 2h - [93]
MWCNT-CS-FA-
NPs
4.1 5:1 6h - [94]
MC/PBAE-1445 82 10:1 4h + [81]
3T
3
† PEI 3 N/A 4h - [79]
dPAMAM 10 N/A 4h - [79]
PD-E 8 PEG 13 3:1* 4h - [79]
Table 1.4: Transfection efficiency using the reporter plasmid pEGFP (Enhanced Green Flu-
orescence Protein) in various mammalian cell lines transfected with cationic polymers com-
monly used for gene transfer. The comparison was done at the optimal charge/ratio (that one
that shows be more efficient) of each lipoplex formulation. *This represent w/w ratio. Fugene
has a protected formulation. †Normalized to total parent events. Abreviations: NMCTS-
graft-PAMAM: N-maleyl chitosan-graft-polyamidoamine. CTS: Chitosan. MWCNT-CS-
FA-NPs: Multi-Walled Carbon Nanotubes (MWCNTs) of different functionalized with chi-
tosanfolic acid nanoparticles. MC: Minicircle DNA. G: Generation of dendrimer. EA-G2
(or EA-G1) was prepared by aminolysis of poly(ethylene glycol)-poly(L-benzyl glutamate)
(PEG-PBLG) using PAMAM G2 (or G1). HT-1080: fibrosarcoma. PMSC’s: Partheno-
genetic Mesenchymal Stem Cell.
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Figure 1.4: The structure of the single cyclized polymer knot. This knotted polymer shows
better transfection capability compared to linear, branched or dendritic polymers. Reprinted
with permission from ref. 79, B. Newland, Y. Zheng, Y. Jin, M. Abu-Rub, H. Cao, W.
Wang, A. Pandit, Single cyclized molecule versus single branched molecule: a simple and
efficient 3D knot polymer structure for nonviral gene delivery. J Am Chem Soc USA, 134,
4782-4789 (2012). Copyrightr 2012, American Chemical Society.
Anderson and co-workers95 reported a high-throughput method for assessing polymer-
mediated transfection. Hundreds of polymers can be tested for gene delivery using 96-well
plates in one day. One limitation of this high-throughput method is the small volumes that
were used for the transfections where polymer-DNA complexation could not be guarantee.
Nevertheless, this method has been already tested with some polymeric based transfection
reagents. From these experiments there appear to be several parameters involved in the
successful design and effectiveness of polymeric transfection reagents: cell type, carrier/DNA
ratio, particle size, toxicity, solubility and stability in serum.
1.4.1 DNA complexation, cellular uptake and DNA release
Polymers due to their cationic nature are capable of interacting and condensing pDNA
to generate nano-sized complexes called poliplexes96. Polymers bind DNA through elec-
trostatic interactions between the phosphate groups present in the DNA and the cationic
groups present in the polymer reagent97 This is an entropic process, with counter ions be-
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ing displaced from both, the DNA and the polymer. Surface charges and the “nitrogen
to phosphate” (N:P) ratios are the primary factors controlling the size and morphology of
the poliplexes98. They adopt structures that are typically blends of toroids and rods, with
diameters ranging from 50-100 nm.
Regardless of the complex’s topology, it is the net positive charge that facilitates the
binding interactions with negatively charged cell surface. Subsequently, they are inter-
nalized, in most cases, through endocytosis99. It has been reported that internalization of
poliplexes (<500 nm in diameter) occurs mostly through receptor-mediated endocytic routes
such as clathrin-mediated endocytosis (CME) and caveolae-mediated endocytosis (CvME).
Particles sizes > 500 nm are taken up by other internalization pathways100. Polymers can
be internalized as well by non-endocytic pathways. Studies carried out by Hong et al.101,102
demonstrated that PAMAM forms small holes in the cell membrane with its subsequently
diffusion into the cell. However, modifications to this polymer such the conjugation to folic
acid switches its enter route to receptor-mediated endocytosis. This indicates that the at-
tachment of certain ligands can be used for targeting purposes to trigger a specific endocytic
route and manipulate the intra-cellular localization of the poliplexes.
It is generally assumed that low to moderate gene expression is due to the trapping
and degradation of the pDNA within intracellular vesicles and limited translocation to the
nucleus28,16. For cationic polymers it is hypothesized that tertiary amine groups become
protonated inside the endosome or (phagolysosome) due to normal acidification processes
leading to an influx of Cl− counter ions to restore charge neutrality. Subsequently, through
osmosis excess water enters the endolysosomes causing membrane rupture103. This contro-
versial process is referred to as proton “sponge escape”104,105. In order for this process to
occur the pKa(s) of the tert-amines must be low enough such that they are unprotonated
at physiological pH and only upon acidification acquire the quaternary form. Some reports
using simulations or direct measurements suggest that more than 50% are already proto-
nated under physiological conditions. In the original paper describing this phenomenon, all
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of the structures that displayed this property were true imines containing a double bond at
the bridging nitrogens21. Nearly all of the plasmid delivery structures produced through the
polymerization of imines have been reduced to tert-amines at the bridging nitrogens, hence
no double bonds. The most recent studies suggest that proton sponge escape is probably not
the driving force for the rupture of the endosomes106,107.The exact mechanism of endosomal
escape is still open to debate.
Some studies suggest that poliplexes must escape the endosomes and release the DNA
into the cytosol. The released DNA then makes its way to the nucleus for transcription19.
However, the translocation of the DNA molecules through the nuclear pores is reported to
be a relatively inefficient process with only 0.1% translocating into the nuclei. It has been
proposed that the DNA is degraded in the cytoplasm and has difficulty traversing the small
diameter of the nuclear pores108. Breuzard et al.109 found using FRET and FRAP analyses
that LPEI-DNA complexes are present in the nucleus. This has raised the question of
how the poliplexes cross the nuclear membrane. The authors suggested that the poliplexes
can undergo modifications in order to pass and fit through the nuclear pores. Also, they
proposed that the plasmid is unpacked in the cytosol and repacked in the nuclei. In contrast
to some polymers, lipids are never found in the nuclei suggesting that only the pDNA is
translocate across nuclear pores110.
While the mechanism of nuclear import of pDNA in poliplexes remains controversial,
clearly the rate-limiting step, which determines transfection efficiency, lies between endoso-
mal escape and translocation across the nuclear pore. Incorporation of nuclear localization
signals and bimetallic nano rods made of Ni/Cu111 that can associate with compacted DNA
and target ligands simultaneously to the nucleus could be potential tools to enhance the
DNA translocation step.
19
1.4.2 Cytotoxicity of polyplexes
Among all of the features of polymers, molecular weight and chain length have the most
impact on transfection efficiency and toxicity. Generally, high-molecular weight polymers
display better transfection rates yet are found to be more toxic for most of cell lines54. The
inherent toxicity of some polymers is an issue that still needs to be addressed. Researchers
are constantly developing novel cationic structures or optimizing existing ones with a variety
of motifs hoping to reduce toxicity80.
PEI, alone, can cause cell necrosis and apoptosis112 and in some cases long-term expres-
sion is not achieved59. Hunter et al.59 presented two phases of PEI cytotoxicity: Phase 1,
cell membrane destabilization and trigger of apoptotic pathways and Phase 2, apoptosis and
loss of Mitochondrial Membrane Potential (MMP), leading to drop the ATP production and
loss of mitochondrial membrane integrity. It was found that N-acylation of a branched 25
kDa PEI can increase its gene delivery efficiency and at the same time reduce its cytotox-
icity113. Conjugation of PEI with homo-bifunctional amine reactive reducible cross-linking
reagents has improved the in vitro gene delivery efficiency in Chinese hamster ovary (CHO)
cells, with a reduction in cytotoxicity89 (Table 1.3). The incorporation of cyclodextrins and
targeting peptides has also raised their transfection efficiency and decreased cytotoxicity114.
Poly-amidoamine (PAMAM) and poly-propylenimine (PPI) are dendrimers that show
high transfection efficiency115. However, the toxicity of dendrimers is the major concern
limiting their medical use. Dendrimers interact nonspecifically with negatively charged
biological membrane forming transient nano-holes leading to leakage of cytoplasmic elements
and cell death116. Several approaches have been tried to reduce their toxicity including the
design of more biodegradable and/or biocompatible dendrimers comprised of peptide and
sugars. Surface modifications such the addition of PEG or Chitosan significantly reduces
toxicity of these complexes117. Recently, Sarkar et al.93, conjugated N-maleyl chitosan
(NMCTS) by Michael type addition reaction to improve solubility, transfection efficiency
and low the toxicity (Table 1.4). Pan et al.92 reported as well high transfection activity with
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moderate toxicity of a copolymer made of poly(ethylene glycol)-poly-(L-glutamine) mixed
with high molecular weight PAMAMs (Table 1.4).
Outstanding issues regarding the bioactivity, metabolism and cytotoxicity of free poly-
mers in the cytoplasm or in sub-cellular components needs to be fully characterized in order
to design a less toxic poly-cations65. There are indications that these molecules could be
used in medicine where cytotoxicity is desired such as cancer chemotherapy.
1.5 Polysaccharide-Based DNA Carriers
1.5.1 Cyclodextrins
Cyclodextrins (CDs) have been extensively studied as non-viral gene delivery vehicles due to
their exceptional biocompatibility and high cation density118. Cyclodextrins by itself does
not form stable complexes with pDNA and this has limited their application as a transfec-
tion system. For this reason they are being use mostly as enhancers with other cationic
polymers or dendrimers due to their ability to make the cell membrane more permeable
by depleting or affecting membrane cholesterol levels91,119 (Table 1.4). However, CDs have
shown potential for gene delivery due to their amphiphilic character, low immunogenicity
and multiple reactive sites available for the attachment of target groups and cations. Cryan
et al.120 modified CDs with pyridylamino, alkylimidazole, methoxyethylamino or primary
amine groups at the 6-position of the glucose and reported significant luciferase expres-
sion in COS-7 cells. Darcy and coworkers121 converted the terminal hydroxyl groups of
CDs into amino groups and obtained transfection efficient on COS-7 cells comparable to
Lipofectamine 2000r.
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1.5.2 Chitosan
Chitosan is a polysaccharide obtained through the chemical treatment of the naturally oc-
curring cross-linked polymer- chitin, the primary constituent of crustacean exoskeletons66.
Chitosan has been extensively studied for non-viral gene therapy due to its exceptional
biocompatibility and high cation density122. Gene delivery efficiency of chitosan is affected
by a number of factors, including molecular weight, counter ions, degree of deacetylation,
and pH12. Even with optimized formulations, the application of chitosan-based gene de-
livery system is still limited by reduced water solubility, inefficient gene unpacking and
low gene transfection efficiency. In recent years, various chitosan derivatives have been
generated aiming to resolve these problems. The structural modification of these newer
chitosan derivatives can be divided into hydrophilic and hydrophobic modifications123. In-
corporation of negatively charged agents such as hyaluronic acid (HA) or poly (L-glutamic
acid) (-PGA) with chitosan has increased its transfection efficiency significantly90,124 (Ta-
ble 1.4). Such improvements in the transfection ability of chitosan-based carriers has been
attributed to the reduced charge density upon the addition of HA chains or the formation
of -PGA/chitosan/DNA complexes that can dissociate into smaller sub-particles after cel-
lular internalization, both of which could improve the release of bound DNA. It should be
noted that the choice of the type and the amount of anionic polymer incorporated to chi-
tosan/DNA complexes greatly influences the transfection ability through changes in cellular
uptake, stability, the size of the nanoparticles, and condensing and dissociating ability of
the DNA. Chitosan has also been conjugated to diverse molecules and polymers such: poly-
L-lysine (PLL), arginine, guanido groups, PEG (Polyethylene glycol), histidine, cysteine,
glutathione, glutamic acid, galactose, targeting peptides and proteins, biotinylated, chon-
droitin sulfate, chitosan nanobubbles, PEI (poly(ethylene-imine), lipid shells and spermine,
with the purpose of lowering the cytotoxicity and increasing DNA delivery efficiency75,125.
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1.6 Peptide DNA carriers
The ability of some peptide sequences to translocate across cell membranes was discovered
serendipitously through the observations of virologist working on the HIV-1 Tat trans-
activating factor and by neurobiologists working on the Drosophila Antennapedia transcrip-
tion factor126. Short basic amino acid sequence segments, rich in arginine residues, were iden-
tified as the critical component responsible for membrane translocation. This region has ben
given the term “peptide transduction domain” (PTD). After this discovery several variations
of cell penetrating peptides (CPPs) have been reported in literature127. They vary signifi-
cantly in their sequence, hydrophobicity, and polarity. However, common features are their
amphipathic character and net positive charge. CPPs can be broadly classified into different
structural categories: cationic peptides, amphipathic peptides, histidine-rich peptides and
peptides containing nuclear localization signal (NLS)128. Older examples of cationic peptides
(or peptides with low amphiphilic character) are poly-L-lysine (PLL)129, polyarginines130,
penetrain131 and TATp132. Examples of amphiphilic CPPs include MAP133, transportan134
and KALA135. Pep-1136 it is a well know amphiphilic peptide but it is has been used mostly
as a protein carrier rather than DNA carrier. Histidine containing peptides, due to the pres-
ence of the imidazole group, can produce membrane destabilization and promote endosomal
release68. A nuclear localization signal sequence has been incorporated to some peptides
(NLS)137 in order to promote the nuclear localization of CPPs upon escaping the endosome.
NLSs are characterized by short clusters of basic amino acids that are recognized and bind
to cytoplasmic receptors knows as imporntins. The most well known NLS comes from the
large tumor antigen of the simian virus 40 (S40) made of only 7 amino acids PKKKRKV.
The conjugation of proteins or peptides to cationic liposomes appears to be a promising
method for improving pDNA delivery in vitro 32. Several publications have reported signif-
icant advances in transfection efficiency using theses combined complexes138,139,140. While
the liposomes can efficiently interact with pDNA and promote endosomal escape, peptides
can aid in targeting the complex to a specific type of cell and even the nuclei. In vivo deliv-
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ery still has drawbacks due to inactivation by serum components, renal excretion and rapid
clearance by immune phagocytic cells if the size of the complexes is below or above 100 nm.
Peptide adducts can affect the size and overall surface of the complexes making them more
suitable for in vivo delivery. Sarker et al.141 synthesized 100 nm arginine-based cationic
lipid nanoparticles. They reported that these nanoparticles, when mixed with DNA, formed
large aggregates in the absence of serum but in the presence of serum small vesicles were
observed. Transfection of HeLa cells with these complexes showed higher efficiency and less
toxicity when compare to Lipofectamine 2000.
To further enhance gene delivery peptides have been conjugated to several synthetic
polymers as well. pTAT sequence has been couple to PAMAM, PEG and PEI142. Kwot et
al.143 explored peptide dendrimers as a new type of transfection reagent. They synthesized a
collection of dendrimers conjugated to different cationic and hydrophobic peptides motifs in
conjunction with the lipid DOTMA/DOPE (Table 1.4). The best results were observed for
G1,2,3-KL ((LysLeu)8(LysLysLeu)4(LysLysLeu)2LysGlySerCys-NH2) with reported trans-
fection efficiency up to 10-fold higher than commercial reagents.
Recently we developed a new type of cationic peptide particle that is comprised of
two self-assembling branched amphiphilic peptides bis-(FLIVIGSII)-K-KKKK (h9) and bis-
(FLIVI)-K-KKKK (h5)
144,145,146. In water, a 1:1 mixture of these two peptides form water-
filled bilayer delimited capsules. Solutes are encapsulated during the assembly process.
When prepared at 25 ◦C and then cooled to 4 ◦C , extremely stable 20-30 nm capsules
are formed that are resistant to temperature, chaotropes, proteases, detergents and the cells
degradative machinery. Initial investigations involving the entrapment and delivery of pDNA
failed as the peptides appear to coat the surface of the DNA and cause its linearization.
Under these conditions the N:P ratio was 65.5. Very low transfection rates were observed
using this method. Subsequent lowering the N:P ratio to near unity results in compaction
of the DNA with the peptides acting like histones. This lower ratio gives much higher
transfection rates ( 20% GFP). Recent refinements are pushing the transfection rates even
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higher and with no measurable toxicity.
Peptide-based gene delivery systems have some advantages over other gene therapy
strategies147. For instance, peptides are more stable, easier to synthesize on a large scale
than lipids, less prone to oxidation, less toxic and are easy to covalently modify with cell
specific recognition ligands148. These ligands include vitamins, cholesterol, metals and an-
tibodies. These adducts can be added through the formation of amines, esters and disulfide
linkages149. Nevertheless, the transfection efficiencies are low compared with the liposomes
and some polymers. Endosomal entrapment and poor nuclear import have been suggested
as the main causes for reduced transfection efficiencies for pure peptide systems148.
1.6.1 DNA-Complexation, cellular uptake and DNA release
Cationic peptides can efficient packed DNA into nanoparticles and prevent their enzymatic
degradation. Peptides containing lysine and arginine have been extensively used for gene
delivery, however the mechanism of how they bind and condense DNA is poorly documented
in comparison to lipoplexes and polyplexes. Mann et al.150, in a recent publication studied
the different patterns of DNA condensation between lysine and arginine based homopeptides
and correlated these structures with gene delivery. By varying the charge ratio and the
length of the homopeptides they characterized six different types of DNA-peptide structures
ranging in a size between 30-350 nm using atomic force microscopy. Results showed that a
lower peptide to DNA charge ratios the tendency is to form road-like structures. Whereas, at
higher peptide to DNA charge ratios compact spheres were observed. The authors proposed
two structures for the arg- and lys-containing complexes. A multi-molecular condensation
pattern for arginine containing peptides, with multiple pDNA molecules associated with the
peptide and a mono-molecular structure proposed with a single pDNA molecule for lysine
containing peptides.
There are many factors that are involved in determining the peptide cellular uptake
including: exposed ligands, particle size, particle shape, cell type, presence of cargo and
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even culture conditions. Currently, it is accepted that peptides can be internalized by two
pathways: non-endocytic and endocytic151. The non-endocytic pathway has three promi-
nent modalities to explain peptide internalization: fusion, inverted micelle and formation of
transient pores in the cell membrane. Some references propose that a tight ionic interaction
between the basic groups of the peptide side chains and the negative charges of the phospho-
lipid heads induce a local invagination of the plasma membrane152. The local reorganization
of the phospholipid bilayer would then lead to the formation of inverted micelles with the
peptide enclosed in the hydrophilic cavity and ultimately resulting in cytoplasmic release.
There are few reliable methods available to definitively identify non-endocytic pathways. For
the energy depend pathways, macropinocytosis seems to be the primary route responsible for
CPP-mediated intracellular delivery of DNA153. However, as previously discussed nanopar-
ticles can simultaneously enter cells through more than one pathway. Antp, nona-arginine,
and the TAT peptide simultaneously used three endocytic pathways: macropinocytosis,
clathrin-mediated endocytosis, and caveolae/lipid raft-mediated endocytosis154.
For cationic peptides, the mode of escape from the lysosome is thought to occur through
an endosomal lysis mechanism similar to that seen for lipoplexes155. Histidine-rich pep-
tides contain ionizable imidazole groups that are partially unprotonated at physiological
pH. Protonation through endosomal acidification could induce rupture of the endosomes
as previously described. It has been suggested that TAT fusion proteins can enter the cell
through endocytosis but escape the endosomal rout similarly thus evading the lysosomal
degradation. Subsequently, they became localize near the perinuclear area156. The rela-
tively low transfection level of PLL-DNA complexes is due possibly to the poor release of
the complexes from endosomal compartments. Incorporation of histidine residues and lipids
such myristic, palmitic and stearic acids have shown improved release into the cytoplasm
with a concomitant increase in transfection efficiency.
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1.6.2 Peptide Cytotoxicity
Peptides are made of natural occurring amino acids and display low toxicity at the con-
centrations typically employed. Very little has been reported in the literature associated
peptide carriers with cell necrosis or apoptosis. This fact and the ability to easily penetrate
cell membranes, could make them potentially the preferred carriers for gene delivery in vitro
and in vivo. As far as we know, alterations in the cell physiology or immune responses have
not been reported for pure peptide gene delivery systems. Hunter et al.59 indicated that
poly-lysines can induce mitochondrial-mediated apoptosis. Cardoso et al.157 have reported
that some amphiphilic peptides can produce membrane perturbations and induce transient
influxes of calcium ions however the report indicates that cell membranes rapidly recovered
and no permanent cell damage was observed.
1.7 Inorganic Nanoparticles
Inorganic nanoparticles are usually prepared from metals (e.g., iron, gold, silver), inorganic
salts, or ceramics (e.g., phosphate or carbonate salts of calcium, magnesium, or silicon)158.
The metal ion salts, in combination with DNA generate complexes with a typical size range
of 10100 nm in diameter. The surfaces of these nanoparticles can be coated to facilitate DNA
binding or target gene delivery. The small particle size offers several advantages including
that they usually bypass most of the physiological and cellular barriers and produce higher
gene expression. They can also be transported through the cellular membranes via specific
membrane receptor or nucleolin, which delivers nanoparticles directly to the nucleus skipping
the endosomallysosomal degradation. These nanoparticles have the ability to efficiently
transfect post-mitotic cells in vivo and in vitro 159. Additionally, they tend to show low
toxicity and are immune silent. Supra-paramagnetic iron oxide-based nanoparticles display
magnetic properties when placed in magnetic fields thereby allowing magnetic field guided
delivery160. Progress in (in vivo) applications of inorganic nanoparticles has accelerated
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recently. However, extensive studies are still required to assess the effect of their types,
sizes, and shapes on transfection efficiency. It is certain that further studies focusing on
long-term safety and surface functionalization will foster future clinical applications.
1.7.1 Gold Nanoparticles
The ability of gold nanoparticles (GNPs) to interact with and enter cells has prompted
researchers to attach various compounds and biological macromolecules to gold in an ef-
fort to combine functionality with cellular uptake. The loading of gold nanoparticles with
drugs or genes offers the prospect of greater control and increased therapeutic efficacy. In
particular, the combination of gold nanoparticles and laser irradiation to control the release
of drugs and genes has the potential to provide useful therapeutic benefits161. The attrac-
tive features of gold nanoparticles include their monitoring by surface plasmon resonance,
the controlled manner in which they interact with thiol groups, and their low-toxicity. Gold
nanoparticles were functionalized with cationic quaternary ammonium groups and then elec-
trostatically bound to plasmid DNA. This composite particle could protect the DNA from
enzymatic degradation and could regulate DNA transcription of T7 RNA polymerase162. In
another report, cationic gold nanoparticles prepared by NaBH4 reduction in the presence of
2-aminoethanethiol formed a complex structure with plasmid DNA expressing a luciferase
gene163. Figueroa et al.164, conjugated gold nanoparticles (AuNP) to polyamidoamine (Fig-
ure 5). AuPAMAM conjugates have been synthesized by crosslinking PAMAM dendrimers
to carboxylic-terminated AuNPs. This new hybrid system was capable of condensing and
delivering pDNA in an efficient manner with low cytotoxicity.
1.7.2 Carbon Nanotubes
Carbon nanotubes (CNTs) consist of carbon atoms symmetrically arranged in sheets of
graphene. Bianco et al.165, were one of the earliest practitioners in the use of carbon
nanotubes for gene delivery. They synthesized a modified carbon nanotube using the 1,
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Figure 1.5: Synthesis of MWCNT-CSFA NP hybrids. Reprinted with permission from ref.
164. E.R. Figueroa, A.Y. Lin, J. Yan, L. Luo, A. E. Foster, R. A. Drezek, Optimization
of PAMAM-gold nanoparticle conjugation for gene therapy. Biomaterials, 35, 1725-1734
(2014). Copyrightr 2014, Elsevier.
3-dipolar cyclo-addition of azomethine. Both single walled carbon nanotubes (SWNTs) and
multi-walled carbon nanotubes (MWNTs) were functionalized with a pyrrolidine ring bear-
ing a free amine-terminal oligo-ethylene glycol moiety attached to the nitrogen atom. This
functional group increased the solubility of carbon nanotubes and enhanced their ability
to bind and condense DNA. CHO cells were transfected using these functionalized car-
bon nanotubes, delivering pDNA containing β-galactosidase as a marker gene166. Nunes et
al.167, have transfected lung epithelial (A549) using carboxylated MWNTs conjugated to
the cationic polymers polyethylenimine (PEI), polyallylamine (PAA), or a mixture of the
two polymers. Liu et al.94, have reported the conjugation of MWNT with chitosan-folic
acid nanoparticles and transfected cells using the gene reporter GFP (Figure 1.6). They
observed an increase on transfection efficiency and reduction of cytotoxicity with this func-
tionalization. Compared to the traditional delivery vehicles, the major advantages provided
by carbon nanotubes are the following: 1) they are easily translocated across cell membrane
2) are capable of achieving spatially- and temporally- controlled release for targeted gene
silencing, 3) their influence on conformation and conformational transitions of DNA/siRNA
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due to their unique shape, modifiable surface chemistry, and their remarkable flexibility,
and 4) their ability to be monitored for therapeutic effects of DNA/siRNA due to their
extremely stable and strong Raman signal and NIR fluorescence emission168.
Figure 1.6: Biocompatible multi-walled carbon nanotube-chitosanfolic acid nanoparticle hy-
brids as GFP gene delivery materials. The scheme demonstrating the synthesis of MWCNT-
CSFA NP hybrids. Reprinted with permission from ref. 94, X. Liu, Y. Zhang, D. Ma, H.
Tang, L. Tan, Q. Xie, S. Yao, Biocompatible multi-walled carbon nanotube-chitosanfolic
acid nanoparticle hybrids as GFP gene delivery materials. Colloids Surf B Biointerfaces,
111, 224-231 (2013). Copyrightr 2013, Elsevier.
1.8 Summary
A significant number of diverse methods are currently available for pDNA delivery in vitro.
Reports are emerging with great frequency describing modified or completely new trans-
fection materials and protocols that do not require virus particles. For chemical carriers,
there are several factors that can affect the transfection efficiency: cell type, carrier/DNA
ratio, particle size, toxicity, solubility and stability in serum. Lipid and polymer base sys-
tems conjugated to peptides or inorganic nanoparticles seem to be the some of the most
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promising non-viral vectors for pDNA gene delivery in vitro. It is important to critically
analyze combination of these elements in order obtain high delivery efficiencies using the
current generation of biomolecules. Researchers are undoubtedly trying to generate the
next generation of amphiphilic cationic molecule capable of overcoming the extracellular
and intracellular obstacles for in vitro and in vivo gene delivery taking into account the
advantages and disadvantages of the current systems. Using current screening technologies
this will be a time- and energy-intensive endeavor. The development of high-throughput
methods for assessing transfection systems is needed and will be vital for optimizing the
numerous parameters involved in this complex process.
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Chapter 2
Branched amphiphilic cationic
oligo-peptides form peptiplexes with
DNA: A study of their biophysical
properties and transfection efficiency
This chapter has been reproduced in its current format with permission from L. Adriana
Avila, Luana R. M. M. Aps, Pinakin Sukthankar, Nicoleta Ploscariu, Sushanth Gudlur,
Ladislav Sˇimo, Robert Szoszkiewicz, Yoonseong Park, Stella Y.Lee, Takeo Iwamoto and
John M. Tomich. submitted to Molecular Pharmaceutics. c©American Chemical Society
2.1 Introduction
The ability to deliver bioactive macromolecules into specific cell organelles holds the promise
of treating a broad range of human diseases3. The first steps required for targeting sub cel-
lular organelles involve traversing the plasma membrane and then gaining access to the
cytosol. Macromolecules such as plasmid DNA (pDNA) are anionic and show greatly re-
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duced membrane bilayer permeability2. Typically they need to be associated with molecular
carriers to facilitate their translocation into the cell.
Adenovirus and retrovirus were the earliest systems used to deliver therapeutic pDNA
and they still remain the first choices due to their high transfection efficiency11. Two
disadvantages of viral gene delivery systems are the possibility of inactivating host genes
through insertional mutagenesis and triggering severe immune responses12. In addition,
previously established immunity to the virus vector and size limitations for packaging larger
pDNAs have limited their clinical applications13.
Safer, non-viral methods are being developed for DNA/RNA packaging and delivery
systems16. While they have been reported to be less efficient than viral vectors, improve-
ments in genome editing systems such as CRISPR/Cas9 and zinc-finger nuclease (ZFN),
have greatly improved integration of corrective sequences by making them site specific17,18.
Adding genome editing elements to pDNA and incorporating them into non-viral gene de-
livery systems has moved gene therapy closer to clinical applications.
A wide range of methods are currently available for pDNA delivery in vitro. Reports
are emerging with increasing frequency describing modified or completely new transfection
materials and protocols that do not require virus particles. Lipoplexes169 (cationic lipid-
DNA complexes) and polyplexes38 (cationic polymer-DNA complexes) are examples of such
non-viral gene delivery systems, which are potentially immunologically inert, as well as safe
and effective gene delivery systems170,171,153. Lipoplexes constitute self-assembling nano-
systems formed as a consequence of branched cationic lipids (e.g. DOTMA, DOTAP, etc.).
Cationic lipids are amphiphilic molecules consisting of a positively charged polar head group
connected to hydrophobic domain via a linker. They spontaneously react quantitatively
with the negatively charged DNA molecules to form complexes, with the cationic lipids
encasing the dsDNA172,173. Successful DNA delivery is known to be dependent on various
factors that include the chemical structure and geometry of the cationic lipids as well as
the supramolecular structure of the lipoplexes57,20. X-ray diffraction studies have revealed
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the presence of a variety of structures for lipoplexes - including lamellar (Lα) phases with
alternating lipid bilayer and DNA monolayers and inverted hexagonal (HII) phase consisting
of DNA coated with a lipid monolayer in a hexagonal lattice174. It has been argued that the
HII phase complexes have a much higher transfection activity then the Lα phase ones. One
explanation could be that this phase promotes the lipoplex fusion with cellular membranes
facilitating the cellular uptake51. However, the high affinity of cationic lipids to DNA reduces
the successful transfection of eukaryotes cells once the DNA/lipid complex is internalized in
the cytoplasm175.
Polyplexes, are made of cationic polymers than bind DNA through electrostatic inter-
actions between the phosphate groups present in the DNA and the cationic groups present
in the polymer reagent97. Polyplexes can adopt diverse nano-structures: blends, toroids or
rods, ranging from 50-100 nm in size. Regardless of the complex topology; it is size, charge
and ability to escape the lysosome and enter the nucleus that appears to be the salient
factors affecting transfection efficiency96.
Peptiplexes, are peptide-DNA complexes that had emerged over the last decade as poten-
tial gene carriers systems176. A pure peptide-based transfection agent has several advantages
over these systems. Peptides can be more stable with regards to oxidation, are easier to
synthesize on a large scale than lipids and polymers, and are relatively easy to modify with
cell specific recognition ligands. However, the mechanism of how they bind to and condense
DNA is poorly documented in comparison to lipoplexes and polyplexes. Mann et al.150 re-
cently studied different patterns of DNA condensation in the presence of lysine and arginine
based homo-peptides and observed a correlation between different shapes of the peptiplexes
and gene delivery efficiency177.
Recently, we reported results on a set of peptides that self-assemble to form stable nano-
capsules144 with lipid-like properties145 that are able to encapsulate, retain and deliver
(in vitro) a variety of solutes into cells, including the alpha-emitting 225Actinium and its ra-
dioactive daughter radionuclides146. The Branched Amphiphilic Peptides Capsules, termed
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BAPCs are potential drug/gene-delivery systems that can be tuned with added ligands to
achieve targeted delivery. The capsules can adopt a range of sizes from 20 nm to several
microns in diameter depending on assembly conditions and are capable of encapsulating
various solutes within the hollow cavity defined by a pure peptide bilayer. Besides being
extremely stable, water-soluble and simple to prepare, these peptide capsules are readily
taken up by cells in vitro.
These amphiphilic peptide sequences were designed to mimic diacyl glycerol phospho-
lipids in architecture and hence have a hydrophilic oligo lysine segment and two identical
hydrophobic tails. The peptide capsules are prepared by mixing equimolar concentrations of
two related peptides: bis(FLIVIGSII)-K-KKKK and bis(FLIVI)-K-KKKK (Fig.2.1). The
hydrophobic core sequence is an internal fragment of the human dihydropyridine sensi-
tive L-type calcium channel segment, CaIVS3. We refer to these peptides as bis(h9)-K-K4
and bis(h5)-K-K4 respectively, where h9 and h5 refer to the number of hydrophobic residues
within the hydrophobic segment. The mixed peptides are referred to as bis(h9:h5)-K-K4 and
as BAPCs only when assembled into capsules or bis(h9:h5)-K-K4-peptiplexes when bound to
DNA.
Figure 2.1: The peptiplexes are comprised of an equimolar mixture of the N-terminal acety-
lated bis(h9)-K-K4 and bis(h5)-K-K4. The molecular weight (MW) of the peptides is 1912.29
and 1655.12, respectively.
Initially we hypothesized that DNA would be encapsulated during the assembly process.
However, we quickly realized that assembly was disfavored in the presence of the poly-anionic
plasmid. We determined that when the peptides are added in great excess they appear to
coat the poly-anionic surface of ds-DNA producing nano-fibers. However, at low peptide
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concentrations we observed compaction of the DNA into nano-spheres type structures.
In this report, we investigated the interactions of these branched amphiphilic peptides
with pDNA and the ability of the resulting peptiplexes to transfect HeLa cells. Different
transfection efficiencies were obtained in each case, with the compacted peptiplexes showing
the highest transfection rates.
2.2 Materials and Methods
2.2.1 Peptide synthesis
Peptides were synthesized as previously described145. The cleaved peptides were then
washed three times with diethyl ether, dissolved in water, and then lyophilized before storing
them at RT. The peptides were purified by reversed phase HPLC and characterized using
matrix-assisted laser desorption/ionization-time of flight (MALDI TOF/TOF). For the mer-
cury containing peptides, an additional cysteine was incorporated at the C-terminus of both
the bis(FLIVIGSII)-K- K4 and bis(FLIVI)-K-K4 peptides. Following cleavage and deprotec-
tion, the cysteine thiol of the both peptides was reacted with 1 equivalent of methylmercury
iodide as previously described145,146.
For peptides covalently labeled with a fluorescent dye; the first amino acid coupled was
Nα-t-Fmoc- Nε-t-boc-Llysine on to a 4-Methylbenzhydrylamine (MBHA) resin (Anaspec
Inc., Fremont, CA). After de-protection of the side chain amino group of the lysine using
80% TFA in dichloromethane chloride (DCM); the N-Hydroxysuccinimide ester of the 5/6-
carboxy-tetramethyl rhodamine was used to couple the dye to the ε-amino site of a lysine
residue in the presence of N,N-Diisopropylethylamine (DIEA). The rest of the synthesis was
carried out as previously detailed145,178.
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2.2.2 Preparation of bis(h9:h5)-K-K4 peptiplexes
The peptides, bis(h9)-K-K4 and bis(h5)-K-K4, were individually dissolved in neat 2,2,2,-
Trifluoroethanol (TFE). Under these conditions the peptides adopt a helical conformation,
thereby forcing the peptides into a monomeric state and ensuring complete mixing. Peptide
concentrations were calculated using the molar absorptivity (ε) of phenylalanine in water at
257.5 nm (195 cm−1 M−1). The bis(h9)-K-K4 and bis(h5)-K-K4 peptides were then mixed
together in an equimolar ratio at 1.25, 2.5, 5, 10, 20, 40 and 50 µM final concentration,
vortexed briefly and allowed to stand for a 10 minutes before removing the solvent under
vacuum. The plasmid containing solution (2.5µg/mL) was added drop-wise into the dried
peptide mixture in autoclaved 1.5 mL Eppendorf tubes and allowed to sit for 10 min at room
temperature before adding CaCl2 at 1.0 mM final concentration. After a 20 min incubation,
the solution was added to the cell culture.
Figure 2.2: A schema of the optimized method to prepare peptiplexes (described in detail
within section 2.2.2
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2.2.3 Confocal Laser Scanning microscopy
Images in Figures 2A, 6, 7 and 8 were taken using a confocal LSM 700 laser-scanning mi-
croscope (Carl Zeiss, Gottingen, Germany). The cell boundary and structure was visualized
using “Differential interference contrast microscopy (DIC)”.
2.2.4 STEM sample preparation
For scanning transmission electron microscopy (STEM) analysis the bis(h9:h5)-K-K4 pep-
tiplexes were prepared as previously described in section (2.2.2) with one exception. The
peptides samples were prepared by co-dissolving 0.7 mole equivalents of bis(h9)-K-K4 and
bis(h5)-K-K4 along with 0.3 mole equivalents of their respective h9 and h5 cysteine con-
taining Me-Hg labeled variants in water to a final concentration containing 0.1 mM each
bis(h5)-K-K4 and bis(h5)-K-K4. The samples were negatively stained for 10 minutes using a
multi isotope 2% Uranyl acetate (Uranium bis(acetato)-O-dioxodihydrate) (Sigma-Aldrich,
St. Louis, MO) aqueous solution. Sample solutions (6 µL) were spotted on to grids and
allowed to stand for 5 min, after which, excess solution was wicked off the grid with a tissue
and allowed to air dry before loading it into the FEI Tecnai F20XT Field Emission Trans-
mission Electron Microscope (FEI North America, Hillsboro, Oregon) with a 0.18 nm STEM
HAADF resolution and a 150X-2306X-106X range of magnification. Scanning transmission
electron microscopy was carried out in the annular dark field mode with a single tilt of 17◦.
2.2.5 Atomic force microscopy (AFM)
The plasmid DNA sample was prepared as described by Li et al.179.For the peptide/DNA
sample, 15 µL of Opti-MEMr I Reduced Serum Media containing the bis(h9:h5)-K-K4 pep-
tiplexes at a ratio equal to 10.4 were deposited onto freshly cleaved mica substrates and
incubated for 15 minutes at room temperature. AFM topography images of immobilized
DNA and peptides were acquired in liquid media using the contact mode on an Innova
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(AFM) from Bruker, USA. The AFM scanner was calibrated using a TGZ1 silicon grating
from NT-MDT, USA. We used MLCT-E cantilevers with their respective nominal spring
constants of 0.1 N/m, and using set point contact forces of 1 nN or less. The AFM topog-
raphy data were flattened by subtracting the background and then plotting them using a
second order equation incorporated in the Gwyddion analysis software180.
2.2.6 Determination of zeta potential
The bis(h9:h5)-K-K4 peptiplexes were prepared as previously described at different charge
ratios and then dissolved in a final volume of 1 mL Opti-MEMr I Reduced Serum Media (Life
Technologies, Grand Island, NY). Zeta-potential for all dispersions were determined using
a Zeta-Potential Analyzer (Brookhaven Instruments Corporation, Holtsville, NY) equipped
with a 677 nm laser. Zeta-potentials (ζ) were determined from the electrophoretic mobility
and Smoluchowski equation, ζ = µη/ε , where η and ε are the viscosity and the dielectric
constant of the medium, respectively. All measurements were performed in triplicates.
2.2.7 Gel Electrophoresis
The bis(h9:h5)-K-K4 peptiplexes were prepared as previously described at different charge
ratios and then dissolved in a final volume of 1 mL Opti-MEMr I Reduced Serum Media.
15 µL of these solutions were loaded on a 0.8% agarose gel containing 0.012% Ethidium
bromide, and run at 60 V for 40 min. A 1 kb ladder was used as reference (Fisher Scientific,
Pittsburgh PA, USA). After electrophoresis, the resulting DNA migration bands were vi-
sualized using a MultiDoc-it, Digital Imaging System (Ultra-Violet Products, Upland, CA,
USA).
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2.2.8 Plasmid digestion with DNase-1
The bis(h9:h5)-K-K4 peptiplexes were prepared as reported above. The nuclease, RQ-1
RNase-free DNase-1 (Promega Corp., Madison, WI) treated samples were prepared accord-
ing to the protocol supplied by the manufacturer. Briefly, 30 µL samples of the bis(h9:h5)-
K-K4 peptiplexes dissolved in Opti-MEM
r I Reduced Serum Media were digested using 1
µL of the nuclease, followed by 4 µL of a 10x reaction buffer (provided by manufacturer).
This sample was incubated for 30 min at 37 ◦C. At the end of the reaction, 4 µL of the
stop solution (provided by manufacturer) was added and the sample incubated for an addi-
tional 10 min at 65◦C to inactivate the DNase. All samples were run in a 0.8% agarose gel
containing 0.012% Ethidium bromide, run at 60 V for 40 min. A 1 kb ladder was used as
reference (Fisher Scientific, Pittsburgh PA, USA). After electrophoresis, the resulting DNA
migration bands were visualized using a MultiDoc-it, Digital Imaging System (Ultra-Violet
Products, Upland, CA, USA).
2.2.9 Cell Culture
HeLa cells were purchased from ATCC (CCL-2). HeLa cells were grown in Dulbeccos
Modified Eagle Medium DMEM (Life Technologies, Grand Island, NY) supplemented with
10% (v/v) fetal bovine serum (Life Technologies, Grand Island, NY) and cells were kept
in a humidified 5% CO2 humidified atmosphere at 37
◦C. All cell lines were passaged by
tripsinization with TrypLETM Express (Life Technologies, Grand Island, NY) every 3rd-4th
day. No antibiotics were added.
2.2.10 Temperature Dependence on Cellular uptake and Lysoso-
mal co-localization of bis(h9:h5)-K-K4 peptiplexes
HeLa cells were seeded on 22 mm culture dishes at a density of 1x105 cells per mL and
grown to roughly 60% confluence. Fresh media at 4 ◦C was added and subsequently, 100 µL
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of media was replaced by a temperature controlled solution containing the bis(h9:h5)-K-K4
peptiplexes prepared with 30% Rhodamine B label on the bis(h5)-K-K4 peptide. Subse-
quently, cells were incubated for 2 h at 4 ◦C, then washed twice with PBS at 4 ◦C and
analyzed using confocal microscopy. The same cell samples were then incubated for an
additional 2 h at 37 ◦C, washed twice with PBS at 37 ◦C and then reanalyzed by confo-
cal microscopy. For the lysosomal immunostaining post incubation with the bis(h9:h5)-K-
K4 peptiplexes cells were fixed in 4% paraformaldehyde (PFA) at RT for 2 h followed by
washes with phosphate-buffered saline containing 1% Triton X-100 (PBS-T, Thermo Fisher
Scientific Inc.). Subsequently, the cells were incubated with mouse anti-lamp 1 antibody
(G1/139/5) for 1 h. The (G1/139/5) hybridoma, developed by Hauri HP.181 was obtained
from Developmental Studies Hybridoma Bank at the University of Iowa. After the incu-
bation, cells were washed three times with PBS-T. Subsequently, were incubated for 3 h
with Alexa 488r labeled goat anti-mouse IgG (Molecular Probes, Carlsbad, CA). Stained
tissues were washed again with PBST and mounted in glycerol containing the nuclear stain
4′,6′-diamino-2-phenylindole (DAPI; 2 µg mL-1; Sigma).
2.2.11 pEGFP-N3 plasmid transfection
Transfection experiments were carried out by mixing a 4.7 kb pDNA, which encodes for
the enhanced green fluorescent protein (EGFP), with bis(h9:h5)-K-K4-peptide equimolar
mixture. The plasmid pEGFP-N3 was obtained from Dr. Dolores Takemoto lab (purchased
from Clontech, Mountain View, CA). HeLa cells were seeded on 22 mm culture dishes at
a density of 1x105 cells per mL, 24 h later at 60% confluence, all medium was removed
from the wells and 800 µL of Opti-MEMr I Reduced Serum Media was added. Next,
200 µL of the different bis(h9:h5)-K-K4 peptiplexes were added to cells and allowed to
incubated in normoxic conditions for 2-6 h. After this incubation, media and transfection
reagent was removed and replaced with 1 mL of fresh DMEM containing 10 % FBS in
each well. The cells were returned to the incubator for 48 h. For the positive control cells
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were transfected with Lipofectinr (Invitrogen, Carlsbad, CA), according to the protocol
supplied by the manufacturer. Some parameters were adjusted to reach optimum results
in HeLa cells. Briefly, lipoplexes where formed in 200 µL Opti-MEMr I Reduced Serum
Media mixing 4 µL of pDNA (2 µg), 8 µL of the transfection reagent and 188 µL of media.
Higher volumes of the reagent led to cell death and lower volumes reduced transfection
efficiency. The lipoplexes were added to the cells and allowed to incubate for 6 h at 37 ◦C.
Transfection efficiency and mean fluorescence intensity were then measured by fluorescence-
activated cell sorting (FACS). Briefly, cell culture medium was removed and cells were
washed once with PBS. Cells were detached by the addition of TrypLETM Express. The
resuspended cells were transferred to 1.5 mL tube and centrifuged for removal of trypsin.
Cells were then resuspended in 250 µL of PBS containing 2% (v/v) FBS and 0.1% (v/v)
propidium iodide (Life Technologies). Analyses were performed on a FACS Calibur, (Becton
Dickinson, Franklin Lakes, NJ, USA). The EGFP-positive/PI-negative cells were counted
as positively transfected cells. The data were analyzed using ANOVA with Bonferroni
post-test. Also, transfection efficiency was monitored by direct counting using confocal
microscopy. Experiments were performed in triplicates.
2.2.12 Cell viability assay
Cell toxicity assays were carried out based on cell death using exclusion of the fluorescent
dye trypan blue. Cells were seeded on 22 mm culture dishes at a density of 1x105 cells per
mL and grown to roughly 60% confluence. Subsequently, 200 µL of the media was replaced
with a media free solution containing bis(h9:h5)-K-K4 peptiplexes. After 6 h incubation
with the bis(h9:h5)-K-K4 peptiplexes all media was removed and replaced with 1 mL of
fresh media per well. After 48 h, all media was removed and cells were washed three times
with PBS. Next, cells were treated for 5 min with 100 L TrypLETM Express to release the
cells from the surface of the wells. The cells were centrifuged and the supernatant was
discarded and the pellet resuspended in 500 µL of PBS. To check for cell viability, 10 µL of
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the resuspended cells were mixed with 10 µL of 2x trypan blue solutions and allowed to sit
for 2 min before counting them in a Cellometerr AutoT4 automated cell counter (Nexcelom
Bioscience LLC, Lawrence, MA). The data were analyzed using ANOVA with Bonferroni
post-test. All experiments were performed in triplicates.
2.3 Results and Discussion
2.3.1 Gene delivery and viability assays of bis(h9:h5)-K-K4 pepti-
plexes
Here, we investigated the ability of bis(h9:h5)-K-K4 peptides to deliver plasmid DNA into
eukaryotic cells. We hypothesized that pDNA could be trapped inside the capsules formed
by the peptides even in the presence of a strong electrostatic interaction between the pep-
tide’s oligo lysyl amines and the anionic DNA backbone phosphates. Modeling studies
provided an estimate of 1600-2000 peptides required for the assembly of our 20 nm diameter
capsules144,145,146.
According to this estimation, transfection experiments were carried out expecting en-
capsulation to occur by providing enough peptides to form one capsule/pDNA strand. The
charge ratio (N:P) between the number of NH3
+’s (N) contained in the oligolysine tails of
the ∼2000 peptides per 20 nm capsule and the number of PO4−’s (P) in the 4.7 kb ds pDNA
was calculated to be 65.5. These parameters were used throughout the experiment however,
only ∼2% of transfection efficiency was observed. This value was deemed quite low and no
more experiments were conducted using these concentrations. Subsequently, we examined
the effect of reduced peptide concentrations with a fixed pDNA concentration (N:P ratios).
Surprisingly at lower N:P ratios the transfection rate in HeLa cells increased nearly 10 fold
(Fig.2.3).
In this experiment HeLa cells were incubated 4 hours with the peptide/DNA complexes
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at different ratios in reduced serum media. Calcium chloride (CaCl2) was added at 1 mM
final concentration to improve transfection efficiency. It has been reported that adding
CaCl2 to Cell Penetrating Peptides (CPP)/DNA complexes can reduce particle size and
maximize gene delivery in vitro 182. However, (CaCl2) by itself is capable of transfecting
mammalian cells in vitro at certain conditions183.To account for this possibility, we studied
the effect of different concentrations (250 µM to 20 mM) of CaCl2 mixed with DNA in HeLa
cells. No GFP expression was observed with CaCl2 final concentrations 1 mM for 6-8 hr
incubations.
Gene delivery efficiency was monitored qualitatively by confocal microscopy and quan-
tified using fluorescence-activated cell sorting (FACS). Propidium Iodide (PI) was used to
identify and then exclude dead cells from the analysis. The GFP-positive/PI-negative cells
were counted as positively transfected cells. As a positive control, cells were transfected
with the commercial transfection reagent Lipofectinr using conditions optimized for this
cell line. Transfection efficiency was reported as the percentage od cells that have been
transfected, despite of the difference in the level of protein production among each cell.
FACS analysis showed that the N:P ratios of 2.6 and 10.4 yielded the highest gene
expression with minimal toxicity. Subsequently, for these two ratios, different transfection
conditions were tested to maximize gene delivery and expression.
We investigated how incubation time affects the transfection rates (Fig. 2.3 B). It was
observed that a 6 h incubation with the peptide/DNA mixture led to the best transfection
rate, particularly for the ratio N:P =10.4. Different buffers were also tested for the 2.6 and
10.4 ratios, being Opti-MEMr I Reduced Serum Media where the peptide/DNA complexes
appeared to be more efficient (Fig. 2.3 C). Fig. 2.3 D shows the effect of 1 mM calcium with
the optimized transfection incubation time and buffer, where according to the Bonferroni
post-test there is no significant difference between the values from the groups 10.4 w/CaCl2
and Lipofectinr.
It is important to note that optimal GFP expression was observed only when the plasmid
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Figure 2.3: Comparison of transfection efficiency of bis(h9:h5)-K-K4 peptiplexes in HeLa
cells. (A) Different peptide to DNA charge ratios (N:P) after 4 h of incubation time with
the complexes in reduced serum media and 1 mM CaCl2 (B) Different incubation times for
the charge ratios 2.6 and 10.4 in reduced serum media and 1 mM CaCl2 (C) Different media
compositions used for transfection after 6 h of incubation with the complexes in reduced
serum media and 1 mM CaCl2. (D) Effect of CaCl2 after 6 h of incubation time with in
reduced serum media and 1 mM CaCl2. Data are presented as means SEM (standard error
of the mean). Differences between values were compared by ANOVA using Bonferroni as
post test. Non-statistical significance (ns) was considered when P>0.05. DPBS: Dulbecco’s
Phosphate-Buffered Saline, calcium and magnesium free
was delivered in the presence of the both branched peptides. The plasmid by itself, when
added directly to the media with or without 1 mM calcium showed no GFP expression.
Transfection with just one of the peptides, either bis(h9)-K-K4, bis(h5)-K-K4 or the linear
sequences FLIVIGSII-K4 and FLIVI-K4 showed minimal GFP expression in comparison
with the bis(h9:h5)-K-K4 peptiplexe with the N:P ratio of 10.4 (Appendix A Fig.A.1). These
results preclude the possibility that the transfection properties of the complex are only due
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to the cationic oligo-lysine segment. Nevertheless, the control sequences mentioned above
are capable of condensing pDNA and facilitating translocation across the cell membrane
(Appendix A Fig. A.2A and A.2B). A possible explanation of why the mixture of the
two branched peptides works better than the linear sequence or just one of them, could
be that both peptides are required to promote the endosomal release of the peptide/DNA
complex. It has been suggested for cationic lipids that incorporation of aliphatic chains with
different numbers and length can improve transfection efficiency by promoting endosomal
escape184,33. These control sequences were tested under the same transfection conditions
that yielded the highest transfection rates.
When one considers the average (n = 3) total number of viable cells per mL (Fig. 2.4A)
after transfecting with bis(h9:h5)-K-K4 peptiplexes at N:P 10.4 and Lipofectin
r, the GFP
yield for the peptiplex is 1.7-fold higher than with the commercial reagent. Our results
show that cell viability is minimally affected by the bis(h9:h5)-K-K4 peptiplexe at the most
effective N:P ratio.
Confocal analysis of living cells (Fig. 2.4B and 2.4C) revealed that the cell morphology
appeared normal after transfection with the peptide/DNA complexes, whereas Lipofectinr
treated cells appeared to have altered morphologies. FACS analysis clearly indicates the
higher efficiency and minimal toxicity of the peptiplexes as compared to the commercial
reagent at its optimized efficiency (Fig 2.4D and 2.4E, respectively). Cationic lipids con-
taining quaternary nitrogen functional groups can bind and inhibit enzymes such as PKC,
which could explain their toxicity60. In addition, cationic lipids can trigger immune re-
sponses and perturb the cell membrane185. Very little has been reported in regard to the
toxicity of peptide carriers causing cell death185. According to results reported by oth-
ers79,141,32 our system appears to be one of the least toxic transfection systems for cells
when compared to several other lipid- and polymer-based transfection methods, suggesting
that it might be safely used for in vivo applications.
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Figure 2.4: (A) Cell viability as determined by trypan blue analysis. (B) Confocal mi-
croscopy images of HeLa cells after transfection with pDNA encoding GFP using the pep-
tiplex at N:P = 10.4 after 6 h of incubation in reduced serum media and (C) Lipofectinr.
FACS analysis of cells transfected with the peptiplex at N:P = 10.4 (D) Lipofectinr (E)
using the same conditions used for the confocal studies. Data are presented as means SEM
The overall P value was determined using 1-way ANOVA using Bonferroni as post test, (ns)
was considered when P>0.05
2.3.2 Biophysical characterization of bis(h9:h5)-K-K4 peptiplexes
Transmission electron microscopy (TEM) of the bis(h9:h5)-K-K4 peptiplexes at charge ratio
of 10.4 revealed compact nanostructures (Fig. 2.5A) compared to plasmid alone (Fig. 2.5B),
whereas the analysis of the ratio where we expected to see encapsulation of the DNA along
the BAPCs (N:P 65.5), generated long strands of DNA. At this high peptide to DNA charge
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ratio the branched peptides appeared to coat the negatively charged backbone phosphate
groups of the dsDNA forming nano-fibers (Fig. 2.5C).
Figure 2.5: TEM images of the peptiplexes at different peptide to DNA ratios. (A) Nano-
omplexes formed at lower charge ratio N:P = 10.4. (B) Plasmid DNA in the absence of
peptide and is shown to compare the different supramolecular structures. (C) Nano-fibers
structures at charge ratio N:P = 65.5. Scale bar = 200 nm
Mann et al.150 reported different patterns of DNA condensation with polylysine and
polyarginine peptides. Their results showed rod and sphere shaped complexes depending
on the charge ratio. However, their results showed an opposite effect when compared to our
results. At higher charge ratios they obtained mostly spheres whereas fibers were obtained
at lower concentrations. These results suggest that our system relies on more than just
electrostatic interactions.
We envision two possible mechanisms that could explain this result. At low N:P ratios
the lysyl groups of monomeric branched peptides associate with the phosphates in the
DNA backbone. Adjacent peptides can then associate through the hydrophobic interactions
of the beta-structure hydrophobic segments thereby constraining the DNA segments in a
compacted conformation. It is also conceivable that small micelle-like patches of peptides
form through the association of multiple hydrophobic segments to shield themselves from
water. This structure leaves the lysines solvent exposed where they are able to interact
electrostatically with different portions of the DNA strands and through bridging, stabilize
the compacted DNA structure. In the case of the high N:P ratio where we see nano-fibers,
the peptides are in large excess over the phosphates and capable of forming bilayers along
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the DNA surface. In the case the DNA becomes a template for the self-assembly of the
peptides and becomes encased (see Fig. 2.6). This model suggests that by adjusting the
N:P ratios different structures can be generated for the complexes. Both models protect
DNA from nuclease cleavage (Appendix A Fig. A.3). The nuclease used in this assay;
DNase-1 cleaves single stranded, double stranded and chromatin DNA and preferentially
cleaves at the 5’ phosphodiester linkages adjacent to pyrimidine nucleotides186.
Figure 2.6: The left panel shows a scenario in which the branched peptide sequences bridge
the DNA at low N:P ratios allowing them to be pulled together. The right panel shows
a hypothetical structure where the DNA is encased within a peptide bilayer. Lysines are
represented by positive charges in the circles
AFM was used to assess the dimensions of the bis(h9:h5)-K-K4 peptiplexes using the
N:P ratio of 10.4:1. Relatively uniform dimensions were observed for the complexes. The
nanostructures displayed heights 70-85 nm and the lateral sizes of around 200-250 nm (Fig.
2.7A and 2.7B). Plasmid DNA vertical height was only about 1 nm (Fig. 2.7C). The
significant change in compaction of the plasmid DNA demonstrates the peptides ability to
interact with and condense DNA.
The zeta potential (ZP) of the nanostructures was also determined at several peptide to
DNA charge ratios previously tested for transfection efficiency (Fig. 2.8B). The ZP can be
defined as the charge that develops at the interface between a solid surface and its liquid
medium. A positive ZP can enhance the interaction with cell membranes however, values
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Figure 2.7: AFM images of the peptiplexes. (A) 3 x 2.4 µm image of the nano-structure
form at N:P of 10.4:1. (B) Cross section analyses of the peptiplex shown in panel A. (C)
Plasmid DNA alone
above 45 mV can be toxic for cells. Particles with negative ZP might not interact effi-
ciently with the negatively charge cell surface. The surface charge for the nanostructure at
N:P=10.4 that led to the highest transfection rate is 5mV, a value suitable to facilitate inter-
actions with negatively cell membrane surfaces but not too high to cause cell damage187,21.
To further confirm the changes in charge and size of the complexes, we analyzed their
electrophoretic mobility in a 0.8% agarose gel (Fig. 2.8A). The first lane shows a 1 kb dsDNA
ladder, lane 2 and 3 contains free pEGFP-N3 plasmid DNA in water and Opti-MEMr I
Reduced Serum Media respectively. Lane 4, represents DNA combined with CaCl2 at 1 mM
final concentration. For 2.6 and 10.4 charge ratios (lanes 5 and 6) a gel shift for the complex
is observed. This shift suggests the formation of a new structure through the association
of peptides with the dsDNA; although only for the N:P = 10.4 is a total DNA retardation
observed. As the peptide/DNA ratio increases, N:P=20.8 (Lane 7) the DNA is fully coated
by a peptide bilayer and ethidium bromide cannot penetrate the complex therefore DNA is
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not visible.
Both methods (electrophoretic mobility and ZP) are analytical measurements that con-
firm the formation of peptide-DNA complexes. In the case of the ZP, the DNA displayed a
negative potential (∼-20 mV) whereas as mentioned above for the peptiplexes at N:P = 2.6
and N:P = 10.4 the ZP is -5 mv and 5mV respectively. This represent a significant differ-
ence in the charge surface between the peptiplexes and DNA. In the agarose gel, different
electrophoretic mobility was observed for only DNA and DNA mixed with different peptide
concentrations.
Figure 2.8: A) Zeta potential of bis(h9:h5)-K-K4 peptiplexes at different peptide to DNA
ratios. (B) Agarose gel electrophoresis of peptide complexes at different ratios, each lane
contains 80 ng of pEGFP-N3. Lane 1 corresponds to 1kb dsDNA Ladder, lane 2 and 3
contains only pEGFP-N3 plasmid in water and Opti-MEMr I Reduced Serum Media re-
spectively. Lane 4 contains DNA + CaCl2 and lanes 5-7 are bis(h9:h5)-K-K4 peptiplexes at
2.6,10.4 and 20.8 respectively.
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2.3.3 Uptake and cellular co-localization of bis(h9:h5)-K-K4 pep-
tiplexes
Cellular uptake of the peptide/DNA complex that displayed the best transfection rate was
monitored using confocal microscopy. For this analysis, the peptide was labeled with Rho-
damine B to permit visualization. To determine whether uptake of bis(h9:h5)-K-K4 pepti-
plexes follows an endocytotic or non-endocytotic route, we employed the most direct and
commonly used method: low temperature (4 ◦C) followed by return to 37 ◦C188. At this
temperature, energy depended endocytotic pathways are inhibited while non-endocytotic
pathways are not102. Non-endocytotic uptake includes (a) membrane fusion and (b) cell
penetration, which is seen in certain cationic peptides containing TAT-like sequences that
can directly penetrate the cell membrane in an energy independent manner189. HeLa cells
were incubated for 2 h at 4 ◦C with the bis(h9:h5)-K-K4 peptiplexes at charge ratio N:P of
10.4 before being washed and imaged. The same cells are then transitioned back to 37 ◦C
and allowed to incubate for an additional 2 h before being re imaged a second time. Con-
focal images of living cells incubated at 4 ◦C failed to internalize the labeled peptide/DNA
complex (Fig. 2.9A) however they appear to be attached to the surface of the cell. Once the
cells were returned to 37 ◦C, normal uptake of the labeled peptide capsules was observed
(Fig. 2.9B). These results indicate that the uptake occurs via a temperature dependent pro-
cess such as endocytosis. At low temperatures the peptide remains bound to the cell surface
even after two washes. Upon raising the incubation temperature, the bound complexes are
readily taken up by the cells. Based on nuclear morphology, cells in (Fig. 2.9A) do not
seem healthy. Cells that were incubated for 2 h at 4◦C showed abnormal nuclear morphol-
ogy, certainly dropping the temperature might compromise cell survival an it is beyond the
scope of this study to determine how this could interfere with the internalization route of
the peptiplexes.
To examine the sub-cellular localization of the bis(h9:h5)-K-K4 peptiplexes after 6 h of
incubation with HeLa cells, both the lysosomes (green) and peptide/pDNA complex (red)
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Figure 2.9: Cellular uptake of bis(h9:h5)-K-K4 peptiplexes at different temperatures. The
nuclei was stained with DAPI (blue) and the peptide bis(h9:h5)-K-K4 was partially labeled
(30%) with Rhodamine B (red). The experiment was done on living cells. (A) Failed cel-
lular uptake of peptide/DNA complexes at 4 ◦C. (B) Incubation of cells with peptide/DNA
complexes at 37 ◦C shows internalization of the peptide. Scale bar = 10 µm
were visualized (Fig. 2.10 panels A-D). Fig. 2.10C shows the merged images of panels
A (complexes) and B (lysosomes). Both co-localized and non-co-localized bis(h9:h5)-K-K4
peptiplexes with lysosomes are observed. These results suggest that the complexes enter
the cell through the endosomal pathway yet at some point they escape most likely due to
endosomal lysis.
The exact endocytic pathway utilized in internalizing the peptide/DNA complex has
not been defined. However, regardless the exact route of entry the peptide/DNA complexes
remain inside the cells without apparent degradation. In Fig. 2.11 cells were transfected with
bis(h9:h5)-K-K4 peptiplexes and after 48 h peptides appear to localize in the peri-nuclear
area with EGFP expression in some of the cells.Cellular uptake at 37 ◦C was observed using
branched peptides containing only D-amino acids (Data no shown). The uptake of the
D-peptide containing complex, suggests that a specific binding interaction does not occur.
We believe that binding of the complex to the cells surface occurs primarily through an
electrostatic interaction.
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Figure 2.10: Lysosomal co-localization of bis(h9:h5)-K-K4 peptiplexes incubated at 37
◦C
with 50 µM 30% Rhodamine B label (A) Red channel for rhodamine (B) Green channel for
lysosomal stain (C) Merge image showing co-localization of bis(h9:h5)-K-K4 peptiplexes and
the lysosomes (yellow). D,D’, EE’ and FF’ are magnification to analyze in more detail the
co-localization of the bis(h9:h5)-K-K4 peptiplexes and the lysosomes . Scale bar upper panel
= 20 µm, lower panel = 10 µm
2.4 Conclusions
Here we report on the formulation of an alternative plasmid DNA/peptide complex that
successfully transfers DNA into cultured cells with good efficiency and low cytotoxicity. As
previously reported the branched peptides bis(h9:h5)-K-K4-peptides form capsules in wa-
ter and act as hollow nano-carriers for small solutes144,145,146. In the case of large anionic
molecules like nucleic acids, capsule formation is not observed. Instead, different structures
are generated based on the charge ratios (N:P) between the peptides and the ds-DNA. At
very high charge ratios the peptides appear to coat the poly-anionic surface of the ds-DNA
forming what appear under TEM long nano fibers. At low charge ratios we observed that
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Figure 2.11: Transient EGFP expression (green) and the peptide bis(h9:h5)-K-K4 partially
labeled (30%) with Rhodamine B (red) in HeLa cells visualized by confocal microscope. Yel-
low spots are the merge of EGFP expression and the peptide. Scale bar=40µM.
the DNA was condensed in compacted structures within different sizes (200-300 nm). The
highest transfection rate was obtained at lower ratios 2.6 and 10.4 in the presence of 1 mM
calcium chloride. Transfection efficiencies superior to the commercial transfection agent,
Lipofectinr were observed when the total number of living transfected cells is taking into
account. The simplicity of the method, low cost (∼1 cent per 1x106 cells) and minimal
cytotoxicity may make this system suitable for in vitro gene delivery where the transformed
cells are to be clonally expanded190. Another potential application could be the use of
this system for in vivo delivery of DNA vaccines, where safe and efficient delivery of plas-
mid DNA to initiate immune response is critical for the success of the therapy5. Unlike
other lipid reagents, which are non-degradable, the non-toxic nature of these peptide-base
nanostructures could potentially facilitate in vivo applications.
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Chapter 3
Branched Amphiphilic Peptide
Capsules (BAPCs) for delivery of
plasmid DNA vaccines.
3.1 Introduction
Nucleic acid-based vaccination offers an attractive option to traditional vaccine strategies
composed principally of attenuated viruses, inactivated pathogens, inactivated bacterial
toxins or recombinant proteins5. Compared to traditional vaccines, DNA vaccines can
generate long-term humoral and cellular immunity191. In addition, DNA vaccines potentially
allow for both prophylactic and therapeutic vaccination5. Furthermore they are relative
inexpensive for manufacture and storage6. It has been shown that injections of naked DNA
into skeletal muscle in animal models result in the expression of the proteins coded by
the added DNA however at low and extremely variable levels, making difficult the design
of a robust and reproducible vaccination system10. Also, the same success achieved in
animal models has not been reported for studies done in humans192. Complexion of DNA
with a biomaterial can improve pDNA-based vaccination. Biocompatible materials such
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lipids, peptides and polymers can enhance DNA stability and cellular uptake5,193. Recently,
peptides have emerged as potential vaccine gene carriers systems194. A pure peptide-based
gene delivery agent would have several advantages over these other biomaterials. Peptides
display stability in regard oxidation and storage and are easier to synthesize on a large scale
than lipids and polymers, and are relatively easy to modify with specific ligands that can
help for targeting purposes129. As far as we know, peptides are the family that has been
less explored as vehicles for DNA vaccine delivery194. P. Locher et al.195 have reported the
enhancement of a human immunodeficiency virus env DNA vaccine using a peptide-based
formulation . This formulation is made of poly-lysines capable to interact electrostatically
with the DNA vaccines. Imidazole moieties were conjugate to the peptide sequence to
facilitate endosomal escape and avoid early intracellular degradation of the DNA. They
reported higher expression of the antigen in comparison to naked DNA delivered by the
intradermal route in BALB/c mice.
Recently, we reported a new class of peptide base nano-capsules termed BAPCs (Branched
Amphiphilic Peptide Capsules). BAPCs are formed by the self-assembly of two branched
peptide sequences bis(FLIVI)-K-K4 and bis(FLIVIGSII)-K-K4 (Fig. 2.1 and 3.1). These
sequences are similar in geometry to phospholipids, the branch point lysine in the sequence
orients the two peptide segments at ∼90◦ angle, as occur with the phosphate bond present
in the diacyl phospholipids. They show other biophysical properties in common with lipids
such the ability to fuse, encapsulate solutes and the possibility to be re-sized.
BAPCs display a uniform size of 20 nm when prepared at 25◦C for 30 min followed
by moving them to 4◦C. These BAPCs retain their size when moved to elevated temper-
atures145. They are taken up by cells in vitro and showed resistance to nucleases and the
cell’s degradative machinery. BAPCs are resistant as well to detergents, proteases and
chaotropes. Recent studies showed the ability of BAPCs to withstand the α-particle emis-
sion and the recoil of daughter radionuclides, in vivo studies demonstrated that the 225Ac
containing BAPCs remained in circulation for 24 h146. The biodistribution of the 225Ac
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Figure 3.1: S/TEM image of BAPCs incubated 30 min in water at 25◦C. To improve
contrast, the peptide sequence bis(FLIVI)-K-K4 was labeled with Hg and mixed at 3:1 ratio
with the no labeled sequence. Scale bar = 100nm
containing BAPCs was different than that observed with free radionuclide. In this report,
we studied the ability of BAPCs to deliver pDNA vaccines capable of targeting Human
Papillomavirus(HPV)-induced tumors in mice.
This pDNA vaccine encodes a fused HPV-16 E7 oncoprotein with the herpes virus gD
protein and it was designed by Dr. Lu´ıs C.S. Ferreira from the vaccine development labora-
tory at University of Sa˜o Paulo196. The aim of the fusion was to maximize the antitumoral
effect. The fusion promotes the enhancement of antigen-specific cytotoxic CD8+ T-cell re-
sponses associated with antitumor protective effects197. The protein E7 is expressed early
in the HPV life cycle and among other proteins from the same family is responsible for the
HPV oncogenic properties. The vaccine promoted the antitumor therapeutic effects based
on the obstruction of coinhibitory signals and the coactivation mechanisms198. The effect of
the vaccine was tested in the C57BL/6 mouse strain. Before vaccination, TC-1 cell epithelial
lung cells expressing the HPV-16 E7 oncoprotein were inoculated into the animals intra-
venously, resulting in a single tumor cell mass at the body flank or pulmonary nodules199.
Significant antitumor therapeutic effects compared with naked DNA vaccines were achieved
when BAPCs were used as a deliver vehicle of the vaccine.
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In our earlier study on using the branched amphiphilic peptides to interact directly
with DNA we saw that the DNA to peptide ratio influenced not only the type of structure
generated but also transfection efficiencies of a double stranded plasmid DNA in cultured
cells (2). Here the peptide capsules were preformed prior to the addition of the pDNA.
These complexes were able to transfect HeLa cells and stably express EGFP in with gene
delivery rates higher that that observed with the commercial reagent Lipofectinr while
showing minimal toxicity.
3.2 Materials and Methods
3.2.1 Peptide synthesis
Peptides were synthesized as previously described145. The cleaved peptides were then
washed three times with diethyl ether, dissolved in water, and then lyophilized before storing
them at RT. The peptides were purified by reversed phase HPLC and characterized using
matrix-assisted laser desorption/ionization-time of flight (MALDI TOF/TOF).
3.2.2 BAPCs preparation
The peptides, bis(h9)-K-K4 and bis(h5)-K-K4, were individually dissolved in pure 2,2,2,-
Trifluoroethanol (TFE) and then mixed together in an equimolar ratio in at 500 µM final
concentration. Peptide concentrations were calculated using the molar absorptivity (ξ) of
phenylalanine in water at 257.5 nm (195 cm−1 M−1). After mixing were allowed to stand for
10 minutes before removing the solvent under vacuum. 1 mL of water was added drop-wise
into the dried peptide mixture in autoclaved 1.5 mL Eppendorf tubes and allowed to sit
for 30 min at 25◦C to form capsules. Subsequently, the capsule containing solution was
incubated for 1 h at 4◦C to stop the capsule fusion. After 1 h, the peptide sample was then
returned to 25◦C for 30 min before mixing with pDNA.
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3.2.3 Preparation of BAPCs-DNA complexes
A plasmid containing solution (2.5µg/mL) was added drop-wise into different tubes contain-
ing BAPCs at different final concentrations (2.5, 5, 10, 20, 40 and 50 µM). This concentra-
tions correspond to the N:P = 1.3, 2.6, 5.2, 10.4, 20.8 and 41.6 respectively. Solutions were
mixed carefully with pipette and allow staying for 10 min before adding CaCl2 at 1.0 mM
final concentration. After 30 min incubation, the solution was added to the cell culture.
Figure 3.2: A schema of the optimized method to prepare peptiplexes (described in detail
within section 3.2.2
3.2.4 STEM sample preparation
For scanning transmission electron microscopy (STEM) BAPCs-DNA complexes were pre-
pared as previously described in 3.2.3. The samples were negatively stained for 10 minutes
using a multi isotope 2% Uranyl acetate (Uranium bis(acetato)-O-dioxodihydrate) (Sigma-
Aldrich, St. Louis, MO) aqueous solution. Sample solutions (6 µL) were spotted on to grids
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and allowed to stand for 5 min, after which, excess solution was wicked off the grid with a
tissue and allowed to air dry before loading it into the FEI Tecnai F20XT Field Emission
Transmission Electron Microscope (FEI North America, Hillsboro, Oregon) with a 0.18 nm
STEM HAADF resolution and a 150X 2306 x 106X range of magnification. Scanning trans-
mission electron microscopy was carried out in the annular dark field mode with a single
tilt of 17◦.
3.2.5 Atomic force microscopy (AFM)
The plasmid DNA sample was prepared as described by Li et al.179. For the peptide/DNA
samples, 10 µL of the BAPCs-DNA complex at N:P = 20.8 was deposited onto freshly
cleaved mica substrates. After a 15 min incubation, the sample was dried under a nitrogen
atmosphere. AFM topography images of immobilized DNA and/or peptides were acquired
in air using the contact mode on an Innova Atomic Force Microscope (AFM) from Bruker,
USA. The AFM scanner was calibrated using a TGZ1 silicon grating from NT-MDT, USA.
We used MLCT-E cantilevers with their respective nominal spring constants of 0.05 N/m
and 0.1 N/m, and using set point contact forces of 1 nN or less. The AFM topography data
were flattened by subtracting the background and using second order line by line fitting
methods incorporated within the Gwyddion software180.
3.2.6 Determination of zeta potential
BAPCs-DNA complexes were prepared as previously described in 3.2.3 at different charge
ratios and then dissolved in a final volume of 1 mL Opti-MEMr I Reduced Serum Media
(Life Technologies, Grand Island, NY). Zeta-potential was measured as described in 2.2.6.
All measurements were performed in triplicates.
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3.2.7 Plasmid digestion with DNase-1
BAPCs-DNA complexes were prepared as reported above (3.2.3) and digested as described
in 2.2.8. All samples were run in a 0.8% agarose gel containing 0.012% Ethidium bromide,
run at 60 V for 40 min. A 1 kb ladder was used as reference (Fisher Scientific, Pittsburgh
PA, USA). After electrophoresis, the resulting DNA migration bands were visualized using
a MultiDoc-it, Digital Imaging System (Ultra-Violet Products, Upland, CA, USA).
3.2.8 DNA/Capsule interaction study with two BAPC tempera-
ture variants
Two different capsule preparation (1.0 mM) schemes were used in this study. One sample
was prepared at 25◦C for 30 min followed by incubation a 4◦C for 1 h, before returning
it to 25◦C for another 30 min (25-4-25◦C BAPCs). The second sample was prepared at
4◦C for 30 min and then transferred to 25◦C (4-25◦C BAPCs). Encapsulation of the auto
quenching fluoresce dye Eosin Y (2.13 mM) occurred during BAPC formation and washed as
previously described145. The washed capsules were suspended in water and mixed with 2.5
µg of pDNA, The samples were analyzed in the fluorometer with excitation at 490nm with
emissions recorded from 495 to 800 nm for 4 h at 15 min intervals using a CARY Eclipse
spectrophotometer (scan rate, 600 nm/min; PMT detector voltage, 800 V; excitation slit, 5
nm; emission slit, 5 nm).
3.2.9 Cell Culture
HeLa cells were purchased from ATCC (CCL-2) and maintained as described in 2.2.9.
3.2.10 Confocal Laser Scanning microscopy
Images in Figure 3B and Suplementary data Fig 1 were taken using a confocal LSM 700 laser-
scanning microscope (Carl Zeiss, Gottingen, Germany). The cell boundary and structure
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was visualized using “Differential interference contrast microscopy (DIC)”.
3.2.11 pEGFP-N3 plasmid transfection
Transfection experiments were carried out by mixing a 4.7 kb pDNA, encoding the enhanced
green fluorescent protein (EGFP). The plasmid pEGFP-N3 was obtained from Dr. Dolores
Takemoto lab (purchased from Clontech, Mountain View, CA). HeLa cells were seeded on
22 mm culture dishes at a density of 1x105 cells per mL, 24 h later at 60% confluence, all
medium was removed from the wells and 800 µL of Opti-MEMr I Reduced Serum Media
was added. Next, 200 µL BAPCs-DNA complexes were added to cells and allowed to
incubated in normoxic conditions for 2-6 h. After this incubation, media and transfection
reagent was removed and replaced with 1 mL of fresh DMEM containing 10% FBS in each
well. The cells were returned to the incubator for 48 h. For the positive control cells were
transfected with Lipofectinr (Invitrogen, Carlsbad, CA), according to the protocol supplied
by the manufacturer. Some parameters were adjusted to reach optimum results in HeLa
cells. Briefly, lipoplexes where formed in 190 µL Opti-MEMr I Reduced Serum Media and
mixed with 2 µg of pDNA and 10 µL of the transfection reagent (Higher volumes of the
reagent led to cell death and lower volumes reduced transfection efficiency). The lipoplexes
were added to the cells and allowed to incubate for 6 h at 37◦C. Transfection efficiency was
evaluated as previously described (2.2.11).
3.2.12 Transfection with pEGFP-N3 plasmid previously treated
with DNase I
BAPCs-DNA complexes at charge ratio of 10.4 and 20.8 were digested for 30 min with DNase
I as previously described in a total volume of 1 mL of Opti-MEMr I Reduced Serum Media.
Subsequently, cell were washed two with PBS and the solution was placed transferred to
cells and incubate for 4 h. 48 h later transfection was monitored by confocal microscopy
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3.2.13 Cell viability assay
Cell toxicity assays were carried out based on cell death using exclusion of the fluorescent
dye trypan blue and PI as previously described (2.2.11 and 2.2.12) at N:P = 1.3, 2.6, 5.2,
10.4, 20.8 and 41.6 values.
3.2.14 DNA vaccine
The circular plasmid DNA vaccine (5.6kb) encoding HPV-16 E7 genetically fused after
amino acid 244 of the HSV-1 gD protein has been described previously by Lasaro et al.200
. To form the BAPCs-vaccine complexes at different N:P ratios (0.65, 1.3 and 2.6), BAPCs
were prepared as we described earlier, and then mixed at 200, 400 and 800 µM with 40 µg
of the DNA vaccine. Each animal was inoculated with a final volume of 100 µL in saline
solution of these complexes
3.2.15 Tumor cell challenge
All animal experiments were conducted with the permission of Biomedical Sciences Institute
of the University of Sa˜o Paulo and housed at the Parasitology Department of the University
of Sao Paulo following the recommendations for proper use and care of laboratory animals.
Groups of 410 mice were injected subcutaneously to the rear flank of the animal with 7.5
X 104 104 TC-1 cells suspended in 100 µl of serum-free medium. The mice were vaccine
with the peptide/DNA formulation three days after the tumoral cell inoculation. Tumor
evolution was checked by visual inspection and palpation for a period of 60 days. The
animals were scored as tumor-bearing when the tumors reached a size of approximately 2
mm in diameter. The mice were euthanized once the tumors showed a diameter of 1 cm or
became necrotic.
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3.2.16 Intracellular cytokine staining
Intracellular IFN-γ staining was done using blood samples from the mice collected 14 days
after vaccine administration following the protocol previously described by Diniz et al.196
for the 0.65 and 1.3 charge ratios.
3.3 Results and discussion
3.3.1 In vitro Transfection Efficiency of the BAPCs-DNA com-
plexes
We assessed the ability of BAPCs to deliver the plasmid pEGFP-N3 in HeLa cells. Cells were
incubated 4 hours with the peptide/DNA complexes at different charge ratios in reduced
serum media (Fig. 3.3A). We define charge ratio (N:P) as the number of NH3+’s (N)
contained in the oligolysine and the number of PO4−’s (P) in the 4.7 kb pEGFP-N3 plasmid.
We tested 6 different formulations based on previous transfection experiments where the
same peptides sequences are mixed directly with the DNA at 25◦C (2).
This treatment condition does not result in capsules formation, instead, depending of
the peptide/DNA ratios; the peptides either coat the plasmid surface forming nano-fibers
or condense the plasmid into nano-sized spherical structures. Calcium chloride (CaCl2) was
added at 1 mM final concentration to improve transfection efficiency. It has been reported
that adding CaCl2 to Cell Penetrating Peptides (CPP)/DNA complexes can reduce particle
size and maximize gene delivery in vitro182. Transfected cells expressing EGFP were visual-
ized by confocal microscopy and quantified using fluorescence-activated cell sorting (FACS).
Propidium Iodide (PI) was used to identify and then exclude dead cells from the analy-
sis. The EGFP-positive/PI-negative cells were counted as positively transfected cells. As a
positive control, cells were transfected with the commercial transfection reagent Lipofectinr
using conditions optimized by the manufacturer for this cell line. FACS analysis showed that
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Figure 3.3: Comparison of transfection efficiency of BAPCs-DNA in HeLa cells. (A)
Different peptide to DNA charge ratios (N:P) after 4 h of incubation time with the complexes
in reduced serum media and 1 mM CaCl2 (B) Different incubation times for the charge ratios
10.4 and 20.8 in reduced serum media and 1 mM CaCl2 (C) Different media compositions
used for transfection of the BAPCs-DNA complexes at N:P = 20.8, after 6 h of incubation
in the absence and presence of CaCl2. Data are presented as means SEM (standard error
of the mean). Differences between values were compared by ANOVA using Bonferroni as
post test. Non-statistical significance (ns) was considered when P>0.05. DPBS: Dulbecco’s
Phosphate-Buffered Saline, calcium and magnesium free.
transfection efficiency differs significantly depending on the peptide to DNA charge ratio.
The ratios that yielded the highest transfection rates were N:P = 20.8 and 41.6, however
cell viability at N:P = 41.6 was almost two-fold lower than the viability observed using 20.8
ratio. Therefore, we discontinued using the higher ratio and we studied how other parame-
ters might affect the transfection efficiency of the 10.4 and 20.8 ratios, We investigated how
incubation time affects the transfection rates (Fig. 3.3B). It was observed that the optimal
incubation time with the complexes was between 4 to 6 h. Although there was no statisti-
cally significant difference between the two time intervals, cell viability was better when the
incubation time is only 4 hours (Data not shown). Once we fixed the suitable charge ratio
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and incubation time, different buffers were also tested in the presence and absence of CaCl2.
We found that transfection rate is the best when Opti-MEMr I Reduced Serum Media is
used as a buffer for the transfection (Fig. 3.3C). According to Bonferroni Test, there is no
significant difference between the complexes incubated with or without CaCl2. Neverthe-
less, we observed after carried out three different experiments a slightly improvement in the
transfection rate (∼8%) based on this observation we have decided to add CaCl2 regardless
the minimal effect on the overall transfection rate. Ultimately these optimized conditions
generated transfection rates approaching 55%, almost twice the transfection rate observed
for the commercial reagent Lipofectinr.
3.3.2 In vitro toxicity of BAPCs-DNA complexes
The in vitro cytotoxicity of the peptide-DNA complexes was evaluated in HeLa cells based
on the dead cell fluorescent marker dyes Trypan blue and propidium iodide (PI) (Fig. 3.4A
and Supplementary data Fig. B.1). The results showed that cell viability is minimally
affected using the DNA/BAPC complex at the N:P ratio yielding the highest transfection
efficiency while the lipid-based transfection reagent caused cell death approaching 50%.
Additionally, confocal analysis shows a normal morphology for those cells that were treated
with DNA/BAPCs whereas treated with Lipofectin displayed abnormal cell structures (2.4B
and 2.4C ).
3.3.3 Biophysical characterization of DNA/BAPC complexes
As previously reported, BAPCs will retain their size (∼20-30 nm) upon incubation at 4◦C.
Based on this fact, we hypothesized that BAPCs could act as cationic nucleation centers
around which DNA could wind, in an analogous fashion to histones compacting DNA to
form nucleosomes. The lysine residues exposed on the outside layer of BAPCs have a
net positive charge thereby facilitating electrostatic interactions with the negatively charge
phosphate groups on DNA polymer. After inspection of 40 images, a well-resolved and
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Figure 3.4: (A) Cell viability after treatment with DNA/BAPC complexes at different N:P
charge ratios as determined by the trypan blue analysis. Viability experiments were done
using the same conditions than transfection. (B) Confocal microscopy images of HeLa cells
after transfection with plasmid DNA encoding the green fluorescent protein (GFP) using
BAPCs: DNA at N:P = 20.8. (C) Bright field images after transfection with plasmid DNA
encoding the green fluorescent protein (GFP) using BAPCs: DNA at N:P = 20.8. Data are
presented as means SEM (standard error of the mean). Differences between values were
compared by ANOVA using Bonferroni as post test. Non-statistical significance (ns) was
considered when P>0.05.
representative transmission electron microscopy (TEM) image of the complex revealed a
uniform coating of single BAPCs with what appears to be a double stranded DNA (Fig.
3.5). However, complexes made up of several BAPCs were more prevalent, suggesting that
the multi-mers comprised of multiple BAPCs and more than one DNA molecule are involve
in the supra-molecular structure of the nanoparticles. The total number of nanostructures
analyzed within the 40 images was 312 and the proportion multi-mers to single BAPCs
was approximately 5:1. According to the polymer random walk model201 pDNA had an
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estimated size of ∼50 nm. However, free DNA molecules generally adopt a much larger size
in solution (∼200 nm)202. For a single 20 nm BAPC, the curvature could be too high for a
single DNA chain to wrap tightly however, since the bending energy is inversely proportional
to the square of the bending circle radius203. Bending of DNA around larger nanoparticle
clusters requires much lower energies. This might explain the presence predominantly of
clusters with average size between 50-100 nm.
Figure 3.5: TEM images of the BACP:DNA assemblies at N:P = 20.8. (A) Single BAPCs
interacting with pDNA (Scale bar = 5 nm). (B) Cluster of BAPCs interacting with DNA.
(C) Schematic representation of the BAPCs-DNA interaction (Scale bar = 100 nm).
AFM imaging was used as a second technique to confirm the topologies of the BAPCs-
DNA complexes at the ratio that displayed the best transfection rate. Using AFM, one can
visualize surface-dependent molecular events in three dimensions on a nanometer scale. At
the N:P = 20.8 using AFM we visualized mostly clusters of several BAPCs interacting with
DNA (Fig. 3.6A). The size distribution of the clusters observed in Fig 3.6A is predominately
between 50-200 nm and match perfectly to what was observed in TEM (Fig. 3.5). Plasmid
DNA “thickness” (or vertical height) is about 1 nm or below (2.7C). A minimum thickness
of the “cluster” is about 5 nm and around 10 nm what confirms that peptide and DNA are
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interacting and forming complexes.
Figure 3.6: AFM images of the DNA/BAPCs at N:P = 20.8. (A) 5 x 4 µm image of
the nano-structure form at N:P of 20.8. (B) Cross section analyses of the DNA/BAPCs
complex shown in panel A, where the nanostructure show a height of ∼ 10nm and length of
∼ 20nm.
According to the two different imaging techniques, BAPCs when are mixed with DNA,
form compact clusters with sizes ranging predominately from 50 nm to 200 nm in average
with a few forming larger assemblies. Among several factors influencing transfection effi-
ciency, particle size is one of the most critical. It impacts both the rate and route of uptake
and cytotoxicity. Rejman et al.204 demonstrated that nanoparticles with a size of 50 nm are
taken up 34 times faster than 100 nm particles and 810 times faster than 500 nm particles.
In regard to cytotoxicity, Yin et al.205 have proposed that the interaction area of bigger
particles is greater than the smaller ones, causing stronger stimulus on the cells, therefore
more chemical reactivity. Most DNA/BAPC complexes appear to be in the suitable range
of size to stimulate transfection.
We investigated the ability of BAPCs to protect bound DNA against nuclease degrada-
tion (Fig. 3.7A). Deoxyribonuclease I (DNase I) was used as a nuclease for this assay and
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cleaves non-specifically at the 5’ phosphodiester linkages adjacent to pyrimidine nucleotides
of double strand DNA186. Results were visualized using agarose gel electrophoresis. The
N:P ratios of 10.4 and 20.8 (lanes 6 and 8 respectively) were able to form tight complexes
with DNA that appeared to avoid endonuclease digestion. No difference was observed when
the bands are compared with the negative controls (lane 5 and 7) of complexes not treated
with the nuclease. The first lane shows a 1 kb dsDNA ladder and lane 2 the free pEGFP-N3
plasmid. Lane 3 contains plasmid mixed only with CaCl2 1mM, conditions where the DNA
is not condensed by the salt. Lane 4 shows the plasmid mixed with CaCl2 and treated
with DNase-1, were no enzyme protection was detected. To further confirm protection,
DNase-1 treated DNA/BAPC complexes were checked for transfection efficiency in HeLa
cells. Under these conditions a significant reduction in the transfection rate was observed
(data no shown), suggesting that DNA could be partially degraded or nicked by the nucle-
ase, most likely due to the fact that some scissile bonds of the DNA remain exposed in the
DNA/BAPC complex.
Figure 3.7: Gel shifts and Zeta potentials of DNA/BAPCs (A) Agarose gel electrophoresis
of peptide complexes at different ratios, each lane contains 80 ng of pEGFP-N3. Lane 1
corresponds to 1kb dsDNA Ladder, lane 2 contains only pEGFP-N3 plasmid, lane 3: DNA
+ CaCl2, lane 4: DNA + CaCl2 + DNase I, lane 5: BAPCs:DNA at N:P = 10.4, lane
6: BAPCs:DNA at N:P = 10.4 + DNase I, lane 7: BAPCs:DNA at N:P = 20.8, lane 8:
BAPCs:DNA at N:P = 20.8 + DNase I. (B) Zeta potential of BAPCs-DNA complexes at
different peptide to DNA ratios.
The BAPCs-DNA complexes zeta potential (ZP) changes from negative to positive when
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the N:P ratio increases, being ∼22mV for the N:P= 20.8, appropriate value to promote cell
surface interaction but not cell damage (Fig. 3.7B). The ZP is a function of the surface
charge which changes when any material is placed in solution. Values above 45 mV could
be toxic for cells and values with a high negative ZP might not interact efficiently with the
negatively charge cell surface.
3.3.4 DNA/Capsule interaction study with two BAPC tempera-
ture variants
After 30 min hydration, BAPCs are a water filled spheres with a homogeneous size of ∼20-
30 nm in diameter (Fig. 3.1). Longer incubation times result in capsule fusion and after
24 h BAPCs can reach sizes up to 1 µm in diameter. Lowering the temperature to 4◦C for
1 h is sufficient to prevent capsule fusion and therefore provides a method to control size.
After this temperature treatment, increasing the temperature or incubation time does not
affect capsule size or cargo release. In our initial vaccine trial 25-4-25◦C BAPCs were used
with success. However in a second trial 4-25◦C BAPCs were used without success. Based
on these results, fluorescence studies looking at the effect of DNA binding with these two
temperature variants were undertaken.
In this experiment 25-4-25◦C BAPCs showed no appreciable change in fluorescence,
suggesting that the capsule’s size remained similar (Fig. 3.8). We have come to refer to this
temperature dependent conformation as the “locked conformation”. A different behavior
in fluorescence intensity was observed when the 4-25◦C BAPCs were mixed with DNA. In
this case, fluorescence rapidly decreased and appeared to reach an endpoint within the first
60 min. This decrease in fluorescence indicates an increase in dye concentration within the
capsule. It should be noted that more capsules form at 4◦C thus accounting for the higher
initial fluorescence intensity206. This increases in concentration could only occur if the 4-
25◦C BAPCs decreased in diameter with the presumed expulsion of water. These results
suggest that the “locked” BAPCs are better for DNA vaccine use.
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Figure 3.8: DNA/capsule interaction study. Washed Eosin Y entrapped 25-4-25◦C (grey)
and 4-25◦C (black) BAPCs were mixed with DNA at N:P = 20.8. at 25◦C. The florescence
emission at nm was measured every 15 min for 60 min
3.3.5 Delivery of HPV-Specific therapeutic antitumor DNA vac-
cines
Diniz et al.196 reported the design of a DNA vaccine capable of targeting HPV tumors. The
vaccine is a 5.6 kb circular plasmid DNA encoding the HPV-16 E7 oncoprotein genetically
fused to the HSV gD protein. This is a pioneer design that has proven to be extremely
efficient in triggering immune responses against HPV-16 tumors. In our study, the ability of
BAPCs to act as a gene carrier and increase potency for the pDNA vaccine was studied. We
administrated BAPCs at different N:P ratios based on the in vitro results previously showed.
For the vaccine delivery at N:P = 1.3 ratio conferred the highest antitumor protection (80%)
to C57BL/6 mice with previously transplanted TC-1 tumor cells (Fig. 3.9). Surprisingly,
lower ratios displayed better transfection in vivo. Around 60% of tumor protection was
detected in animals injected only with DNA + CaCl2 and approximately 20% was achieved
by the peptide-DNA complexes with an N:P = 0.65 and 2.6. The control with only saline
solution showed no tumor protection. The vaccines were tested in groups of five mice and
vaccines were administrated 3 days after the injection of tumor cells.
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Figure 3.9: Administration of a single vaccine dose containing DNA/BACP’s complexes
at different N:P charge ratios. Vaccines were administered intramuscularly 3 days after
injecting the TC-1 cells. Figure provided by Dr. Lu´ıs C.S. Ferreira and Luana R. M. M.
Aps from the vaccine development laboratory at University of Sa˜o Paulo
The induction of antigen-specific CD8+ T-cells response was measured as well since
it directly related with the therapeutic tumor protection. CD8+ T-cells exert antitumor
cytolytic activity and are also implicated in the destruction of virally infected cells. Figure
3.10 shows that the administration of the vaccine complexes with BAPCs increased the
activation of E7-specific IFN-γ producing CD8+ T cells in mice 3 days after the TC-1
cell challenge, particularly for the charge ratio of 1.3. No significant immune response
was detected for the control group (only saline). Lower responses were detected for only
DNA or the 0.65 and 2.6 N:P groups. These results confirmed the enhanced therapeutic
antitumor protection observed in the mice immunized with the DNA/BAPC complexes.
Greater cytotoxic activity against tumor cells and reduction in tumor mass was detected
when BAPCs were co-administrated with the enhance DNA vaccine.
3.4 Conclusions
In summary, we report the ability of a peptide capsules to safely deliver plasmid DNA
in vitro and in vivo. These pre-formed peptide capsules are prepared in water at 25◦C and
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Figure 3.10: Percentage of CD8+ IFN-γ+ cells of total CD8+ T cells in mice immunized
with different DNA/BAPC complexes at different N:P charge ratios. Data represent results
of one immunization of two experiments with similar results, each data point represent one
animal. Differences between values were compared by ANOVA using Bonferroni as post
test. Non-statistical significance (ns) was considered when P>0.05.Figure provided by Dr.
Lu´ıs C.S. Ferreira and Luana R. M. M. Aps from the vaccine development laboratory at
University of Sa˜o Paulo
subsequently cooled to 4◦C to prevent fusion and preserve the particle size around 20-30 nm.
They interact with plasmid DNA acting as a cationic nucleation centers were DNA wraps
around, generating DNA/BAPCs complexes with a size ranging mainly between 50-250
nm that displayed a positive zeta potential. Both of these parameters are appropriate for
gene delivery. One possible explanation for the increase in transfection rates in comparison
with the method that was previously reported (2) might be the reduction in size of the
peptide/DNA complex. Also the presence of a cationic surface should enhance cellular
uptake and subsequent release from the late endosomes. The AFM images show some larger
clusters that appear to be around 500 nm. It is unclear whether these participate complexes
participate in the delivery process.
HeLa cells transfected with the DNA/BAPCs complexes showed around 55% for GFP
expression, almost two-fold that observed for the same gene and same cell line by the
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commercial reagent Lipofectinr. Taking into account the viable cells per mL (4.5x105), the
protein yield is almost four times when compared to Lipofectinr. While some transfection
reagents displayed high transfection efficiencies in vitro, they often lose their ability to reach
the same results for in vivo applications207. BAPCs are capable to enhancing the therapeutic
effect of an optimized DNA vaccine that encodes for the oncoprotein E7. The TC-1 cell
transplantation model was using to monitor E7-specific CD8+ T-cell responses against and
tumor development. After 60 days of the T-cell transplantation, 80% of the mice were tumor
free. This represents a clear improvement in the antitumor protection vs. the group of mice
treated only with naked DNA (60
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Chapter 4
Conclusions
We developed a new peptide-base method to deliver plasmid DNA into eukaryotic cells.
DNA is a large anionic molecule with limited ability to penetrate cells without the presence
of a carrier or shocking the cell. Synthetic non-viral DNA carriers are cationic molecules that
bind to DNA, predominantly through electrostatic interactions and promote the cell mem-
brane translocation. In these studies two relatively short branched peptide sequences were
prepared that proved to function as a synthetic non-viral carriers of plasmid DNA. The se-
quences bis(FLIVIGSII)-K-KKKK and bis(FLIVI)-K-KKKK, are capable of self-assembling
into extremely stable nano-capsules that are able to encapsulate, retain and deliver (in vitro)
a variety of solutes into cells. To date, these include the alpha-emitting 225Actinium and
its radioactive daughter radionuclides and various fluorescent dyes146.
Initially, we hypothesized that pDNA could be trapped inside the capsules formed by
the peptides. Based on this premise, transfection experiments were carried out expecting
encapsulation to occur by providing enough peptides to form one capsule/pDNA strand.
The charge ratio (N:P) between the number of NH3+’s (N) contained in the oligolysine tails
of the ∼2000 peptides per 20 nm capsule and the number of DNA backbone phosphates (P)
in the 4.7 kb ds pDNA was calculated to be 65.5. These parameters were used throughout
the experiment however, only a ∼2% transfection efficiency was observed. When these pep-
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tide/DNA complexes were analyzing using TEM, we observed long nano-fibrils with lengths
of 0.5-1 microns. However, since transfection efficiencies were quite low no more experiments
were conducted using these proportions. Subsequently, we examined the effect of reduced
peptide concentrations at a fixed pDNA concentration. Surprisingly, at lower N:P ratios
transfection rate in HeLa cells increased nearly 10 fold reaching rates nearly 25%. Struc-
tural analyses of the peptide/DNA complexes for these ratios reveled spheric morphologies
with sizes ranging from 100-500 nm in diameter. For this nanostructure we used AFM in liq-
uid phase as a second technique to confirm the structure pattern of the complexes. In both
cases (fibers and nano-spheres), the DNA in water was added to the dried peptides with an
incubation time of 30 min before adding them to in vitro cultured HeLa cells. Although we
managed to increase the transfection rate by modifying the peptide/DNA charge ratio, we
felt higher transfection rates could be obtained that would be comparable to those obtained
using commercial synthetic transfection reagents. Pursuing this, we discovered that if the
peptide capsules, termed BAPCs were pre-formed in water for 30 min at 25◦C followed by
cooling at 4◦C for 1 h and then before adding DNA at 25◦C, better transfection rates might
be achieved. We refer to this temperature shift regime as 25-4-25◦C and was identified
previously by Sukthankar208. Here BAPCs displayed a uniform size of ∼20 nm and they
retain their size at elevated temperatures and are resistant to disruption by organic solvents.
Images generated by TEM and AFM for the resulting DNA/BAPC complexes revealed that
BAPCs remained intact and bound plasmid DNA acting as a cationic nucleation centers
were DNA wraps around, generating peptide-DNA complexes with a size between 50-250nm.
The size reduction of the DNA/BAPC complexes might be a possible explanation for the
increase in transfection rates in comparison with the methods previously described. Among
several factors influencing transfection efficiency, the particle size is one of the most critical
since have an impact in the rate and route of uptake and their cytoxicity. Rejman et al.204
demonstrated that nanoparticles with a size of 50 nm are taken up 34 times faster than 100
nm particles and 810 times faster than 500 nm particles. In regard cytotoxicy, Yin et al.205
78
have proposed that the interaction area of bigger particles is greater than the smaller ones,
causing stronger stimulus on the cells, therefore more chemical reactivity and potentially
more toxic effects. In summary, we discovered different patterns of DNA condensation by the
peptide sequences bis(FLIVIGSII)-K-KKKK and bis(FLIVI)-K-KKKK FLIVV depending
on the peptide/DNA charge ratio and the method of preparation (4.1). Each conformation
displayed different gene delivery efficiency. The structure where the DNA wraps around
display much higher transfection efficiencies in HeLa cells in comparison with the other two
morphologies and the commercial lipid reagent Lipofectinr. Similarly, pDNA was delivered
in vivo, as a vaccine DNA encoding E7 oncoproteins of HPV-16. It elicited an immune
response activating CD8+ T cells and provided anti-tumor protection in murine models.
Figure 4.1: (A) Peptiplexes forming nano-fibers structures at N:P = 65.5, scale bar =
200nm (B) Peptiplexes forming nano-spheres complexes formed at N:P = 10.4, scale bar
= 200nm.(C) BACP:DNA assemblies at N:P = 20.8, scale bar = 100nm. D, E and F are
schematic plots of the different DNA/peptide assemblies respectively.
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4.1 Future Directions
Several factors can influence transfection efficacy such as cell type, carrier/DNA charge
ratio, particle size, particle charge, toxicity, solubility and stability in serum185. For in vitro
delivery the parameters described here were optimized exclusively for HeLa cells using a
reporter gene GFP. It would be relevant to test our delivering method in different cells
types and using different plasmids, or even different type of nucleic acids such a RNA.
BAPCs are relatively easy and cheap to synthesize in comparison with some polymers that
often require extra purification steps209,210,211. Compared to lipids, these peptide sequences
appear to be less toxic and more stable (for instance less susceptible to oxidation), giving
an advantage for manufacture and storage29,212.Other peptides systems have showed to be
efficient transfection reagents, however for some cases high concentration of peptide is needed
causing reduction in cell viability88,213. Also, often peptides must be conjugate to other
molecules such lipids or polymers in order to reach high transfection rates213. Potentially,
BAPCs could be a commercial alternative for the current market of transfection reagents
due to their low toxicity, stability and relatively high transfection rate.
While some transfection reagents displayed high transfection efficiencies in vitro, they
often lose their ability to reach the same results for in vivo applications. BAPCs have
been improved the therapeutic effect of an optimized DNA vaccine that encodes for the
oncoprotein E7. Studies are currently in progress to find out if a second round of the
same vaccine formulation will enhance the antitumoral effect. Also, preliminary data using
blood biomarkers for three organs (heart, liver and kidney) in mice demonstrated that
BAPCs are not toxic in the concentration range used for vaccination. Several vaccines
against HPV-induced tumors have been tested in clinical studies, however none of them have
reach licensing for human use214. Problems associated with reproducibility and antitumor
protection emerged in some of theses methods215,216,217. If we succeed in optimize the
vaccine formulation to reach values near to 100% of tumor protection and reproducibility,
this vaccine method could find application in future clinical trials on HPV and other viral
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mediated cancers.
In another series of experiments DNA/BAPCs were able to transfect Drosophila melanogaster
cell lines (data no shown), suggesting that BAPCs are capable of penetrate a variety of cell
types. We are currently testing the ability of BAPC’s to transfect gram positive or gram
negative bacteria. Other experiments being considered involve using BAPCs to deliver DNA
and dsRNA orally.
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Appendix A
Supplementary Data for Chapter 2
Figure A.1: Comparison of transfection efficiency of bis(h9:h5)-K-K4 peptiplex and different
peptide control sequences at the same N:P ratio of 10.4. Peptide-DNA complexes were
incubated 6 h in reduced serum media and 1.0 mM CaCl2. Data are presented as means
SEM (standard error of the mean).
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Figure A.2: (A) Agarose gel electrophoresis of peptide complexes with different peptide
sequences at N:P=10.4, each lane contains 100 ng of pEGFP-N3. Peptiplexes were in
Opti-MEMr I Reduced Serum with 1 mM CaCl2. Lane 1: 1kb dsDNA Ladder, lane 2:
bis(h9:h5)-K-K4 peptiplex, Lane 3: Branched sequence bis(h5)-K-K4 only, Lane 4: Branched
sequence bis(h9)-K-K4 only, Lane 5: Linear sequence (FLIVI)-K-K4, Lane 6: Linear se-
quence (FLIVIGSII)-K-K4. (B) Celluar uptake of the branched peptide sequence bis(h5)-K-
K4 partially labeled with Rhodamine B
Figure A.3: Agarose gel showing the results of bis(h9:h5)-K-K4 peptiplex samples treated
with DNase-1. Lane 1: 1kb dsDNA Ladder, Lane 2: plasmid (pEGFP-N3), lane 3: plasmid
(pEGFP-N3) treated with DNase-1, lane 4: plasmid (pEGFP-N3) + CaCl2 1.0 mM, lane 5:
plasmid (pEGFP-N3) + CaCl2 1mM treated with DNase-1, lane 6: bis(h9:h5)-K-K4 peptiplex
at N:P = 10.4, lane 7: bis(h9:h5)-K-K4 peptiplex at N:P=10.4 treated with DNase-1, lane
8: plasmid (pEGFP-N3) lane 9: bis(h9:h5)-K-K4 peptiplex at N:P = 65.5 and lane 10:
bis(h9:h5)-K-K4 peptiplex at N:P=65.5 treated with DNase-1. Lanes 7 and 10 show complete
protection of pDNA. Lanes 3 and 5 show complete degradation of the plasmid.
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Appendix B
Supplementary Data for Chapter 3
Figure B.1: Cell viability after treatment with DNA/BAPC complexes at different N:P
charge ratios as determined by PI analysis. Viability experiments were done using same
conditions than transfection.
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